

kimia farma

LabKlinik



National Market Acquisition Through Outstanding Performance

2021 | Laporan Tahunan
Annual Report

PT Kimia Farma Diagnostika



JEJAK LANGKAH

MILESTONE

Unit Bisnis
Labklinik sebagai Unit Bisnis melengkapi Portofolio Bisnis PT. Kimia Farma (Persero) Tbk.

Business unit
Clinical Lab as a Business Unit complements the Business Portfolio of PT. Kimia Farma (Persero) Tbk.

2003

Entitas
Menjadi Entitas mandiri sebagai PT Kimia Farma Diagnostika (anak perusahaan PT Kimia Farma Apotek).

Entity
Become an independent entity as PT Kimia Farma Diagnostika (a subsidiary of PT Kimia Farma Apotek).

2010

Integrasi
Integrasi Layanan Klinik Kimia Farma ke KFD.


Integration
Integration of Kimia Farma Clinic Services into KFD.

2020

Jaringan Layanan Kesehatan
Menjadi jaringan layanan kesehatan (klinik dan laboratorium) terbanyak di Indonesia.

Healthcare Network
Became the largest network of health services (clinics and laboratories) in Indonesia.

2021



KESINAMBUNGAN **TEMA** THEME CONTINUITY

GROWING FAST TO BE A NEW CHALLENGER



2020



PETA INDONESIA

INDONESIAN MAP






478

Jejaring Outlet

Outlet Network



- 72** Laboratorium Klinik
Laboratory Clinic
- 13** Dokter Praktek Perorangan
General Practitioner
- 15** Klinik Specialistik
Clinical Specialist
- 378** Klinik Pratama
Primary Care



DAFTAR ISI

TABLE OF CONTENTS

2	Jejak langkah Milestone
3	Kesinambungan Tema Theme Continuity
4	Peta Indonesia Indonesian Map
6	Daftar Isi Table of Contents
IKHTISAR DATA KEUANGAN DAN OPERASIONAL Financial and Operational Highlights 	
10	Tinjauan Keuangan Financial Overview
13	Peristiwa Penting Event Highlights
LAPORAN MANAJEMEN Management Report 	
22	Laporan Dewan Komisaris Board of Commissioners Report
26	Laporan Direksi Board of Directors Report
PROFIL PERUSAHAAN Company Profile 	
36	Data Perusahaan Company Data
37	Sekilas Perusahaan Company Overview
37	Bidang Usaha dan Wilayah Operasional Line of Business and Operational Area
38	Struktur Organisasi Organizational Structure
40	Visi, Misi, Budaya, dan Nilai-Nilai Inti Perusahaan Vision, Mission, and Corporate Value
42	Makna Logo Definition of Logo
43	Profil Dewan Komisaris Board of Commissioners Profile
45	Profil Direksi Board of Directors Profile
50	Profil Pejabat Eksekutif Executives Profile
64	Demografi Karyawan Employee Demographics
67	Struktur Kimia Farma Diagnostika Grup Structure of Kimia Farma Diagnostika Group
68	Penghargaan dan Sertifikasi Awards and Certification
69	Daftar Alamat Kantor Bisnis <i>Manager</i> PT Kimia Farma Diagnostika List of Address of Business Office <i>Manager</i> of PT Kimia Farma Diagnostika
71	Informasi pada Situs Web Perusahaan Information on Company Website

ANALISA & PEMBAHASAN MANAJEMEN Management Discussion & Analysis 	
74	Tinjauan Keuangan Financial Overview
84	Struktur Modal Capital Structure
FUNGSI PENUNJANG BISNIS Business Supporting Function 	
90	Sumber Daya Manusia Human Capital
TATA KELOLA PERUSAHAAN Corporate Governance 	
96	Perkara Penting Legal Case







IKHTISAR DATA KEUANGAN DAN OPERASIONAL

FINANCIAL HIGHLIGHTS AND OPERATIONAL

2021 Laporan Tahunan
Annual report



TINJAUAN KEUANGAN

FINANCIAL OVERVIEW

LAYANAN KFD

KFD SERVICES

PENDAPATAN BERDASARKAN SEGMENT WILAYAH

REVENUE BY REGIONAL SEGMENT

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017
Jawa Java	350.479	297.482	111.749	81.046	56.975
Sumatera	128.369	76.070	31.684	20.029	20.881
Sulawesi dan Maluku Sulawesi and Maluku	76.756	43.072	23.576	17.786	-
Kalimantan	56.599	33.612	10.780	9.172	-
Bali dan Nusa Tenggara Bali and Nusa Tenggara	27.740	26.330	4.208	1.911	25.362
Jumlah Total	639.943	476.566	182.041,65	129.942	103.218

PENDAPATAN BERDASARKAN SEGMENT TUNAI – KREDIT

REVENUE BY CASH – CREDIT SEGMENT

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017
Tunai Cash	285.524.860.119	169.783.742.145	41.715.424.068	28.131.174.099	22.305.774.615
Kredit Credit	354.418.015.431	306.781.785.812	140.326.229.382	101.811.313.384	80.912.157.460
Jumlah Total	639.942.875.550	476.565.527.957	182.041.653.450	129.942.492.483	103.217.932.075

IKHTISAR KEUANGAN

FINANCIAL HIGHLIGHTS

LAPORAN POSISI KEUANGAN KONSOLIDASIAN

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020- 2021%	CAGR 2017- 2021%
Aset Lancar Current Assets	474.548	280.514	109.239	72.925	30.373	69,17%	73,28%
Aset Tidak Lancar Non-Current Assets	82.479	64.036	49.096	31.706	9.468	28,80%	54,18%
Jumlah Aset Total Assets	557.027	344.550	158.335	104.631	39.841	61,67	69,48%
Liabilitas Janglan Pendek Current Liabilities	360.260	231.815	64.163	15.438	8.095	155%	158%
Liabilitas Jangka Panjang Non-Current Liabilities	5.774	3.720	1.061	777	442	155%	90%
Jumlah Liabilitas Total Liabilities	366.035	235.535	65.224	16.215	8.537	155%	156%
Jumlah Ekuitas Total Equity	190.992	109.015	93.111	88.417	31.304	175%	57%



LAPORAN LABA RUGI DAN PENGHASILAN KOMPREHENSIF LAINNYA KONSOLIDASIAN

CONSOLIDATED STATEMENTS OF PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020-2021%	CAGR 2017-2021%
Penjualan Sales	639.943	476.566	182.042	129.942	103.218	134%	58%
Beban pokok Penjualan Cost of Goods Sold	(262.885)	(296.956)	(80.493)	(52.085)	(44.858)	89%	56%
Laba Kotor Gross Profit	377.058	179.609	101.549	77.857	58.360	210%	59%
Biaya Usaha Operating Income	(237.351)	(150.369)	(91.207)	(67.758)	(49.974)	158%	48%
Laba Usaha Operating Income	139.708	29.241	10.342	10.100	8.386	478%	102%
Beban Keuangan Finance Cost	-	-	-	41	183	0%	0%
Laba Sebelum Pajak Income Before Tax	139.708	29.241	10.342	10.059	8.260	478%	103%
Penghasilan Income Tax Benefits (Expense)	(30.310)	(6.794)	(2.829)	(2.808)	(2.260)	446%	91%
Laba Tahun Berjalan Income for the Year	109.398	22.446	7.514	7.250	6.000	487%	107%
Komprehensif Lainnya (Expense)	1.136	1.475	81	(137)	(357)	77%	0%
Laba Komprehensif Comprehensive Income	110.533	23.922	7.594	7.113	5.643	462%	110%

LAPORAN ARUS KAS KONSOLIDASIAN

CONSOLIDATED STATEMENTS OF CASH FLOWS

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020-2021%	CAGR 2017-2021%
Arus Kas dari Aktivitas Operasi Activities	104.272	126.290	(13.499)	(4.387)	1.895	83%	172%
Investasi Activities	(34.032)	(20.536)	(20.789)	(26.380)	(2.353)	166%	95%
Kas dan Setara Kas Cash Equivalents	(112.233)	(57.408)	50.290	48.000	2.131	196%	0%
Terhadap Kas dan Setara Kas	(41.992)	48.346	15.993	17.234	1.673	-87%	0%
Effects on Cash and Cash Equivalents	-	-	-	-	-	0%	0%
Kas dan Setara Kas Awal Tahun Early Year	88.776	40.340	24.438	7.204	5.531	220%	100%
Kas dan Setara Kas Akhir Tahun End of Year	46.784	88.776	40.340	24.438	7.204	53%	60%
Investasi Investment	-	-	-	-	-	0%	0%



RASIO - RASIO KEUANGAN
FINANCIAL RATIO

Keterangan Description	2021 Audit	2020 Audit	2019 Audit	2018 Audit	2017 Audit
Imbal Hasil Investasi Return on Investment	321%	109%	36%	27%	255%
Imbal Hasil Ekuitas Return on Equity	57%	21%	8%	8%	19%
Imbal Hasil Aset Return on Assets	25%	8%	5%	7%	15%
Margin Laba Kotor Gross Profit Margin	59%	38%	56%	60%	57%
Margin Laba Bersih Net Profit Margin	17%	4,7%	4,1%	5,6%	5,8%
Rasio Perputaran Aset Asset Turnover Ratio	142,0%	189,5%	138,5%	179,9%	279,6%
Rasio Lancar Current Ratio	132%	121% ^o	170%	472%	375%
Rasio Cepat Quick Ratio	13%	38%	63%	158%	89%
Rasio Utang Jangka Panjang Long Term Debt Ratio	3,0%	3,4%	1,1%	0,9%	1,4%
Rasio Liabilitas Terhadap Jumlah Aset Liability to Total Assets Ratio	68%	41%	41%	15%	21%
Rasio Liabilitas Terhadap Ekuitas Liability to Equity Ratio	192%	216%	27%	18%	70%



PERISTIWA PENTING

EVENT HIGHLIGHTS

8  JANUARI | JANUARY 2021



Kunjungan Dinas Kesehatan Kota Lampung

Kunjungan dari Dinas Kesehatan Kota Lampung ke Kimia Farma Diagnostika cabang Lampung dalam rangka survei perizinan relokasi laboratorium medis cabang Lampung.

Lampung City Health Office Visit

A visit from Lampung city health office to Kimia Farma Diagnostika Lampung branch in the context of a survey for license on relocation of Lampung branch medical laboratory.

1  MARET | MARCH 2021



Kerja Sama dengan PT Kertas Padalarang

Kerja sama antara KFD dengan PT Kertas Padalarang untuk pelayanan inhouse klinik dan medical check up pegawai.

Cooperation with PT Kertas Padalarang

Cooperation between KFD and PT Kertas Padalarang for in-house clinic and employee medical check-up services.

4  MARET | MARCH 2021



Kerja Sama dengan PT KAI Cab Palembang

Kerja sama antara KFD dengan PT KAI Cab Palembang untuk pelayanan medical check up pegawai.

Cooperation with PT KAI Cab Palembang

Cooperation between KFD and PT KAI Palembang branch for employee medical check-up services.

9  MARET | MARCH 2021



WoW Brand PT Kimia Farma Diagnostika

Kimia Farma Diagnostika menjadi Gold Champion of Indonesia WOW Brand 2021 di sektor Laboratorium Klinik.

WoW Brand PT Kimia Farma Diagnostika

Kimia Farma Diagnostika becomes the Gold Champion of Indonesia WOW Brand 2021 in the Clinical Laboratory sector.



12



MARET | MARCH

2021



Kerja Sama dengan Kemenpora

Rapid Test Antigen Piala Kemenpora sebanyak 20.000 Tes. Pelaksanaan pada tanggal 21 Maret 2021.

Cooperation with the Ministry of Youth and Sports Kemenpora Cup

Antigen Rapid Test as many as 20,000 tests, held on March 21, 2021.

8



APRIL | APRIL

2021



Kerja Sama untuk COVID-19 test dan MCU

Kimia Farma Diagnostika bekerja sama dengan Perusahaan di Industri Otomotif untuk pelayanan pemeriksaan COVID-19 dan Medical Check Up.

Cooperation for COVID-19 test and MCU

Kimia Farma Diagnostika collaborated with companies in the Automotive Industry for COVID-19 inspection services and Medical Check Ups.

9



APRIL | APRIL

2021



Penandatanganan Kerja Sama BPJS Kesehatan

Penandatanganan Kerja Sama antara Kimia Farma Diagnostika dengan BPJS Kesehatan untuk Pelayanan Prolanis area Kalimantan Barat.

BPJS Health Cooperation Signing

Signing of Cooperation between Kimia Farma Diagnostika and BPJS Health for Prolanis Services for West Kalimantan area.

1



JUNI | JUNE

2021



Kebijakan Non-Tunai (Cashless)

Kimia Farma menetapkan kebijakan transaksi non-tunai (cashless) untuk meningkatkan pelayanan dan kemudahan bagi pelanggan.

Cashless Policy

Kimia Farma establishes a cashless transaction policy to improve service and convenience for customers.



19  **JUNI | JUNE** **2021**



Pelaksanaan Kegiatan Vaksinasi Gotong Royong Bekerja Sama dengan Perbanas

Kimia Farma Diagnostika melakukan kegiatan vaksinasi COVID-19 (VGR) bekerja sama untuk pegawai Bank yang bergabung dalam persatuan Bank Umum Nasional dengan estimasi peserta 30.000.

Gotong Royong Vaccination Activity in Collaboration with Perbanas

Kimia Farma Diagnostika held COVID-19 vaccination activity (VGR) in collaboration for Bank employees who join the National Commercial Bank union with an estimated 30,000 participants.

20  **JUNI | JUNE** **2021**



Pelaksanaan MCU Rikkes Berkala Polda Jawa Barat

Kimia Farma Diagnostika bekerja sama dengan Polda Jabar untuk melakukan pelayanan *medical check up* dengan Peserta 1.103 orang.

West Java Regional Police's Periodic Rikkes MCU

Kimia Farma Diagnostika collaborated with West Java Regional Police to provide medical check-up services with 1,103 participants.

17  **JULI | JULY** **2021**



Pelaksanaan Kegiatan Vaksinasi Gotong Royong Bekerja Sama di Jababeka

Kimia Farma Diagnostika melakukan kegiatan vaksinasi COVID-19 (VGR) untuk karyawan di daerah Jababeka dengan estimasi peserta 3.000.

Gotong Royong Vaccination Activity in Jababeka

Kimia Farma Diagnostika held COVID-19 vaccination activity (VGR) for employees in Jababeka area with an estimated 3,000 participants.

18  **JULI | JULY** **2021**



Pelaksanaan Kegiatan Vaksinasi Gotong Royong di KIIC Karawang

Kimia Farma Diagnostika melakukan kegiatan vaksinasi COVID-19 (VGR) untuk karyawan di daerah KIIC Karawang dengan estimasi peserta 4.000.

Gotong Royong Vaccination Activity in KIIC Karawang

Kimia Farma Diagnostika held COVID-19 vaccination activity (VGR) for employees in KIIC Karawang area with an estimated 4,000 participants.



3  **AGUSTUS | AUGUST** **2021**



Pelaksanaan Kegiatan Vaksinasi Gotong Royong Bekerja Sama PT Astra Agro Lestari

Kimia Farma Diagnostika melakukan kegiatan vaksinasi COVID-19 (VGR) untuk karyawan PT Astra Agro Lestari di daerah Sumatera, Kalimantan, Sulawesi dengan estimasi peserta 36.000.

Gotong Royong Vaccination Activity in collaboration with PT Astra Agro Lestari

Kimia Farma Diagnostika held COVID-19 vaccination activity (VGR) for employees of PT Astra Agro Lestari in Sumatra, Kalimantan, Sulawesi with an estimated 36,000 participants.

12  **AGUSTUS | AUGUST** **2021**



Pelaksanaan MCU Rikkes Berkala Polda Jawa Timur

Kimia Farma Diagnostika bekerja sama dengan Polda Jawa Timur untuk melakukan pelayanan *medical check up* dengan Peserta 1.001 orang.

East Java Regional Police's Periodic Rikkes MCU

Kimia Farma Diagnostika collaborated with East Java Regional Police to provide medical check-up services with 1,101 participants.

3  **SEPTEMBER | SEPTEMBER** **2021**



Penandatanganan Perjanjian Kerjasama Layanan Kesehatan Nasabah Bank Mandiri Taspen

Kimia Farma Diagnostika bekerja sama dengan Bank Mandiri Taspen untuk melakukan pelayanan Kesehatan bagi Nasabah Bank Mandiri Taspen.

Signing of Bank Mandiri Taspen Customer Health Service Cooperation Agreement

Kimia Farma Diagnostika collaborates with Bank Mandiri Taspen to provide health services for Bank Mandiri Taspen customers.

14  **SEPTEMBER | SEPTEMBER** **2021**



Grand Opening Klinik Kimia Farma Labuan Bajo – Nusa Tenggara Timur

Grand Opening Klinik Kimia Farma Labuan Bajo yang dihadiri oleh Wakil Bupati Kab Manggarai Barat, Ka Dinkes, Ka Bandara Komodo, Ka Dinas Lingkungan Hidup, Ka Dinas PTSP, Kepala Puskesmas. Selain peresmian klinik, KFD juga memberikan bantuan lewat program "Kita Bersama Nakes" berupa 1.000 paket Fituno, vitamin C, dan vitamin D3 untuk para nakes serta 1.000 Fituno sirup untuk anak nakes di Kabupaten Manggarai Barat.

Grand Opening of Kimia Farma Labuan Bajo Clinic – East Nusa Tenggara

Grand Opening of Kimia Farma Labuan Bajo Clinic, attended by the Deputy Regent of West Manggarai Regency, Head of Health Office, Head of Komodo Airport, Head of Environmental Service, Head of PTSP Service, Head of Public Health Center. In addition to the inauguration of the clinic, KFD also gave a donation through the "We are here with the Health Workers" program in the form of 1,000 packages of Fituno, vitamin C, and vitamin D3 for health workers and 1,000 Fituno syrup for health workers in West Manggarai Regency.



8  **OKTOBER | OCTOBER** **2021**



Pembentukan Serikat Pekerja (SP) Kimia Farma Diagnostika
 Pembentukan Serikat Pekerja Kimia Farma Diagnostika yang dihadiri oleh Direksi KFD, Ketua Serikat Pekerja PT Kimia Farma Tbk, Ketua dan SekJen Serikat Pekerja KFA, Para Manager KFD, Para Bisnis Manager KFD dan Perwakilan Pegawai KFD.

Establishment of Kimia Farma Diagnostika Labor Union (SP)
 The establishment of Kimia Farma Diagnostika Labor Union, was attended by the Directors of KFD, the Chair of PT Kimia Farma Tbk Labor Union, the Chair and Secretary General of KFA Labor Union, KFD Managers, KFD Business Managers and KFD Employee Representatives.

21  **OKTOBER | OCTOBER** **2021**



Grand Opening Laboratorium Klinik Kimia Farma Mataram – NTB
 Grand Opening Klinik Kimia Farma Mataram yang dihadiri oleh Walikota Mataram, Ka Dinkes Kota Mataram, Direktur Umum & Human Capital PT Kimia Farma Tbk, Kepala KKP Provinsi NTB dan Kepala BPJS Kota Mataram. Selain peresmian Lab.Klinik, acara tersebut dilengkapi dengan program CSR PT Kimia Farma Tbk berupa 1.000 dosis Vaksin COVID-19 dengan jenis vaksin Sinopharm untuk Masyarakat kota Mataram – NTB.

Grand Opening of Kimia Farma Clinical Laboratory Mataram – NTB
 Grand Opening of Kimia Farma Mataram Clinic, attended by the Mayor of Mataram, Head of Mataram City Health Office, General & HC Director of PT Kimia Farma Tbk, Head of KKP NTB Province and Head of BPJS City Mataram. In addition to the inauguration of the Clinic Lab, the event was complemented by PT Kimia Farma Tbk CSR program Tbk in the form of 1,000 doses of COVID-19 vaccine with Sinopharm type of vaccine for the people of Mataram city - NTB.

8  **OKTOBER | OCTOBER** **2021**



Grand Opening Klinik Kimia Farma Kamkey – Papua
 Grand Opening Klinik Kimia Farma Kamkey yang dihadiri oleh Ka Dinkes Kota Papua, Kepala BPJS Kota Papua dan Mitra BUMN setempat serta dihadiri oleh perwakilan adat Papua.

Grand Opening of Kimia Farma Clinic Kamkey – Papua
 Grand Opening of Kimia Farma Kamkey Clinic, attended by the Head of Papua City Health Office, the Head of BPJS City of Papua and local BUMN partners and attended by Papuan customary representatives.

14  **NOVEMBER | NOVEMBER** **2021**



Grand Opening Layanan Klinik dan Labklinik Subang– Jabar
 Pembukaan layanan klinik dan labklinik di Kabupaten Subang. Peresmian layanan kesehatan yang bertepatan dengan telah ditetapkannya Jajaran Direksi terbaru dari PT Kimia Farma Diagnostika.

Grand Opening of Subang–Jabar Clinic and Labclinic Services
 Opening of clinic and laboratory services in Subang Regency. The inauguration of health services which coincided with the appointment of the latest Board of Directors of PT Kimia Farma Diagnostika.



14  NOVEMBER | NOVEMBER 2021



Launching Layanan Vaksinasi Immunicare

Launching Layanan Vaksinasi Immunicare oleh Komisaris Utama PT Kimia Farma Apotek, Soleh Udin Al Ayubi, PhD dan penyerahan secara simbolis kepada Bupati Subang berupa program CSR dari PT Kimia Farma Tbk berupa 1000 dosis vaksin COVID-19 dan 100 dosis vaksin Influenza.

Launching of Immunicare Vaccination Service

Launching of Immunicare Vaccination Service by the President Commissioner of PT Kimia Farma Apotek, Soleh Udin Al Ayubi, PhD and a symbolic handover to the Regent of Subang in the form of a CSR program from PT Kimia Farma Tbk. with 1000 doses of COVID-19 vaccine and 100 doses of Influenza vaccine.

8  DESEMBER | DECEMBER 2021



Gebyar Vaksin dan Bakti Sosial Vaksin VGR

Kimia Farma Diagnostika dan Perusahaan Listrik Negara (PLN) sebagai perusahaan BUMN ikut berkolaborasi dengan memberikan kontribusi melalui pemberian 1000 dosis vaksin Sinopharm dan sembako bagi masyarakat Jawa Barat.

Vaccine Festival and VGR Vaccine Social Service

Kimia Farma Diagnostika and the State Electricity Company (PLN) as state-owned companies were collaborating by donating 1000 doses of Sinopharm vaccine and basic necessities for the people of West Java.

11  DESEMBER | DECEMBER 2021



Gerai Vaksinasi VGR Kabupaten Ciamis

Gerai Vaksinasi 1000 dosis vaksin COVID-19 di daerah Ciamis dan Tasikmalaya. Besar harapan kolaborasi ini akan mempercepat target pencapaian vaksinasi sebesar 70% sampai akhir tahun 2021 di Jawa Barat.

Ciamis Regency VGR Vaccination Outlet

Vaccination outlet for 1000 doses of COVID-19 vaccine in Ciamis and Tasikmalaya areas. It is hoped that this collaboration will accelerate the target of achieving vaccination by 70% until the end of 2021 in West Java.

16  DESEMBER | DECEMBER 2021



Program CSR Vaksin VGR

Program CSR PT Kimia Farma Tbk dan PLN Persero menggandeng Kimia Farma Diagnostika sebanyak 20.000 Dosis Vaksin COVID-19 Sinopharm dan sembako untuk masyarakat di Kabupaten Seram Bagian Timur, Maluku.

VGR Vaccine CSR Program

CSR Program of PT Kimia Farma Tbk and PLN Persero cooperated with Kimia Farma Diagnostika, with as many as 20,000 doses of Sinopharm COVID-19 vaccine and basic necessities for the people of East Seram Regency, Maluku.

HALAMAN SENGAJA DIKOSONGKAN
This page is intentionally left blank

Klini



ik



kimia farma
LabKlinik



LAPORAN MANAJEMEN

Management Report

2021 Laporan Tahunan
Annual report



LAPORAN DEWAN KOMISARIS

BOARD OF COMMISSIONERS REPORT

Ir. RETNO SUMEKAR, M.Sc

KOMISARIS UTAMA
PRESIDENT COMMISSIONER





Pemegang saham yang terhormat, dengan mengucapkan puji syukur kehadiran Allah SWT, Tuhan Yang Maha Esa karena atas berkat rahmat dan karunia-Nya, proses kegiatan usaha PT Kimia Farma Diagnostika selama tahun 2021 berjalan dengan baik. Adanya wabah COVID-19 yang mengakibatkan secara keseluruhan perekonomian global mengalami penurunan, akan tetapi stabilitas bisnis dan kinerja Perseroan masih dapat dikategorikan cukup baik, yaitu dengan membukukan pendapatan usaha sebesar Rp640 miliar atau terjadi kenaikan sebesar 34,17% dibandingkan tahun sebelumnya yaitu Rp477 miliar. Berdasarkan analisa keuangan penurunan ini terjadi pada triwulan kedua dan seterusnya yang utamanya berasal dari pendapatan segmen pemeriksaan COVID-19. Menyikapi terjadinya penurunan pendapatan usaha, Dewan Komisaris berupaya dengan keras untuk memastikan pengawasan pelaksanaan strategi Perseroan tetap berada di jalur yang tepat, agar Perseroan dapat mencapai target yaitu bersepakat dengan *Board of Director* mengembangkan program baru sesuai kebutuhan pasar. Sementara itu, untuk aset tercatat sebesar Rp557 miliar, naik sebesar 61,67% dari tahun sebelumnya yaitu Rp344,55 miliar. Kenaikan tersebut khususnya berasal dari kenaikan pendapatan Perseroan dan investasi bisnis dalam pengembangan usaha. Dewan Komisaris secara rutin melakukan pemantauan dan memberikan nasihat kepada Direksi melalui rapat untuk membahas persoalan strategis sampai dengan operasional. Dengan membangun komunikasi yang baik dan rutin, Dewan Komisaris berkomitmen untuk menjalankan fungsinya dengan optimal.

Dewan Komisaris mengapresiasi prospek usaha yang telah disusun Direksi untuk mencapai target tahun 2021. Dewan Komisaris menilai gambaran prospek usaha yang disusun oleh Direksi dalam bentuk Rencana Kerja dan Anggaran Perusahaan (RKAP) yang berdasarkan pertimbangan dan analisis yang tepat, dan dibuat berdasarkan data-data yang akurat. Sebagai Dewan Komisaris setiap saat memberikan masukan kepada Direksi dalam hal penyusunan rencana dan target sehingga tetap memperhatikan kondisi eksternal maupun internal Perseroan. Dewan Komisaris memberikan

Dear shareholders, let us sending abundant gratitude to Allah SWT, the Almighty God, because of His mercy and grace, the business process of PT Kimia Farma Diagnostics in 2021 managed to be running well. The COVID-19 outbreak caused the overall global economy to decline, but the business stability and performance of the Company can still be categorized as favorable, namely by recording revenue amounted to Rp640 billion or an increase of 34.17% compared to the previous year amounted to Rp477 billion. Based on financial analysis, this decline occurred in the second quarter onwards, which mainly came from revenue from the COVID-19 inspection segment. Responding to the declining revenue, Board of Commissioners strives to ensure that the supervision of the Company's strategy implementation remains on the right track, so that the Company can achieve the target, which has been agreed upon by the Board of Directors, to develop new programs according to market needs. Meanwhile, assets were recorded at Rp557 billion, an increase of 61.67% from the previous year, which was Rp344.55 billion. The increase mainly came from the increase in the Company's revenue and investment in developing its business. Board of Commissioners routinely monitored and provided advice to the Board of Directors through meetings to discuss strategic to operational issues. By building good and regular communication, Board of Commissioners is committed to carrying out its functions optimally.

Board of Commissioners appreciates the business outlook prepared by the Board of Directors in order to achieve the 2021 target. Board of Commissioners considers that the description of the business outlook in the form of Corporate Work Plan and Budget (RKAP) has been laid on appropriate considerations and analysis, and based on accurate data. Board of Commissioners at all times provides input to the Board of Directors in terms of preparing plans and targets, to always pay attention to external and internal conditions of the Company. Board of Commissioners would like to



apresiasi kepada Direksi atas pencapaian kinerja Perseroan yang sangat baik di tahun 2021, dimana jajaran Direksi telah mampu menghadapi tantangan perubahan perekonomian dan bisnis dalam mengembangkan program keberlanjutan yang efektif, dan menjalankan Tata Kelola Perseroan yang baik di masa yang penuh tantangan. Sebagai penutup, izinkan Dewan Komisaris menghaturkan rasa terima kasih kepada seluruh pemegang saham serta Direksi dan karyawan, atas kolaborasi, komunikasi dan kerja sama yang telah terjalin dengan baik. Dewan Komisaris berharap agar seluruh kontribusi positif yang telah dicapai di sepanjang tahun 2021 menjadi tantangan bagi PT Kimia Farma Diagnostika untuk terus bertumbuh dan mewujudkan visi dan visinya.

express a highest appreciation to the Board of Directors for excellent performance achieved by the Company in 2021, in which the Board of Directors has been able to face the challenges of the economy and business in developing effective sustainability programs and implementing good corporate governance in such in challenging times. As final words, please allow Board of Commissioners to express gratitude to all shareholders as well as the Board of Directors and employees, for the collaboration, communication and cooperation that have been well established. Board of Commissioners hopes that all positive contributions that have been achieved throughout 2021 will be a challenge for PT Kimia Farma Diagnostika to continue to grow as well as to realize its vision and mission.

Jakarta, 23 Mei 2022
Atas Nama Dewan Komisaris PT Kimia Farma Diagnostika
Jakarta, May 23, 2022
On behalf of the Board of Commissioners of PT Kimia Farma Diagnostika



Ir. RETNO SUMEKAR, M.Sc
Komisaris Utama
President Commissioner

HALAMAN SENGAJA DIKOSONGKAN
This page is intentionally left blank



LAPORAN **DIREKSI**

BOARD OF DIRECTORS REPORT

**drg. ARDHY NUGRAHANTO WOKAS,
MSc PH., MSc HM., Ph.D., DIC., MSCO.**

**DIREKTUR UTAMA
PRESIDENT DIRECTOR**





“Kecepatan adaptasi dan inovasi dalam memanfaatkan peluang disertai dengan perbaikan proses bisnis yang meliputi Restrukturisasi Organisasi, Penguatan Sistem Layanan Digital, Sinergi dengan Stakeholder, Audit Sistem Pengawasan Internal dan Quality Assurance. Kami lakukan demi menjaga pertumbuhan kinerja Perseroan dan kepercayaan customer dalam industri layanan kesehatan khususnya Laboratorium Medis.”

“The speed of adaptation and innovation in taking advantage of opportunities, accompanied by improvement of business processes which include Organizational Restructuring, Strengthening Digital Service Systems, Synergy with Stakeholders, Internal Monitoring System Audits and Quality Assurance, have been carried out in order to maintain the Company's performance growth and customer trust in the health service industry, especially Medical Laboratories.”

Puji syukur kami panjatkan kepada Tuhan Yang Maha Esa atas rahmat dan ridho-Nya kepada kita semua, sehingga Perseroan dapat melewati tahun 2021 dengan memberikan pencapaian, kinerja dan kontribusi terbaik dalam sektor Layanan Jasa Kesehatan pada Laboratorium Medis. Pembinaan, Inovasi dan kolaborasi menjadi faktor pendorong pertumbuhan terutama pada bisnis inti layanan kesehatan. Pada kesempatan ini perkenankanlah kami menyampaikan laporan kepengurusan Perseroan untuk tahun buku 2021.

TINJAUAN EKONOMI DAN INDUSTRI BESERTA TANTANGAN

Dalam menjalankan kegiatan di tengah kondisi perekonomian dunia yang melambat, Direksi berupaya dengan bersungguh-sungguh dalam menjalankan kegiatan usaha. Ekonomi dunia sempat melambat bahkan terhambat oleh kemunculan COVID-19 varian baru, semua negara berupaya untuk bangkit dari pandemi COVID-19 dan mendorong pemulihan ekonomi, termasuk Indonesia. Oleh karena itu diperlukan kebijakan yang saling melengkapi baik dari sisi kesehatan maupun ekonomi, agar kedua sisi tersebut bisa pulih bersamaan. Hal ini didasari oleh pulihnya kepercayaan masyarakat secara cepat dalam melakukan aktivitas ekonomi, menjadikan momentum pemulihan di sisi *demand* dan *supply* tetap terjaga.

Ekonomi Indonesia tahun 2021 tumbuh sebesar 3,69%, lebih tinggi dibandingkan pencapaian tahun 2020 yang mengalami kontraksi pertumbuhan sebesar 2,07%. Dari sisi produksi, pertumbuhan tertinggi terjadi pada Lapangan Usaha Jasa Kesehatan dan Kegiatan Sosial sebesar 10,46%, sementara dari sisi pengeluaran pertumbuhan tertinggi dicapai oleh Komponen Ekspor Barang dan Jasa sebesar 24,04%. Kemudian, Ekonomi Indonesia triwulan IV-2021 terhadap triwulan IV-2020 mengalami pertumbuhan sebesar 5,02% (y-on-y). Dari sisi produksi, Lapangan Usaha Jasa Kesehatan dan Kegiatan Sosial mengalami pertumbuhan tertinggi sebesar 12,16%. Sementara dari sisi pengeluaran,

Praise and gratitude be upon God Almighty, since due to His grace and blessing to all of us, the Company can sail through the year of 2021 by recording the best achievements, performance and contributions in the Health Services sector, especially Medical Laboratory. Improvement, innovation and collaboration are the driving factors for business growth, particularly in health services business. On this delightful occasion, please allow us to submit a report on the management of the Company for the 2021 fiscal year.

ECONOMY AND INDUSTRY OVERVIEW AND THE CHALLENGES

Board of Directors strives earnestly in carrying out business activities in the midst of slowing world economic conditions. The world economy had slowed down and was even hampered by the emergence of a new variant of COVID-19. All countries are trying to rise from the COVID-19 pandemic and incite economic recovery, including Indonesia. Therefore, complementary policies are needed, both in terms of health and economy, so that both sides can recover at the same time. This is based on rapid recovery of public confidence to do economic activities, keeping the momentum of recovery in terms of demand and supply maintained.

The Indonesian economy in 2021 grew by 3.69%, higher than the achievement in 2020 which experienced a growth contraction of 2.07%. In terms of production, the highest growth occurred in the Health Services and Social Activities Business at 10.46%, while in terms of expenditure the highest growth was achieved by the Export Component of Goods and Services at 24.04%. The Indonesian economy in the fourth quarter of 2021 compared to the fourth quarter of 2020 grew by 5.02% (y-on-y). In terms of production, the Health Services and Social Activities Business Field experienced the highest growth of 12.16%. Meanwhile, in terms of expenditure, the Export Component of Goods



Komponen Ekspor Barang dan Jasa mengalami pertumbuhan tertinggi sebesar 29,83%.

KEBIJAKAN STRATEGIS

Kimia Farma Diagnostika memiliki kebijakan yang bertujuan untuk meningkatkan kualitas layanan dan *sustainability growth* Perseroan yang *sustain* sejalan dengan kebutuhan layanan kesehatan masyarakat. Dengan tujuan menjadi perusahaan Layanan Jasa Kesehatan yang profesional, terkemuka dan mampu memberikan solusi Layanan Jasa kesehatan bagi seluruh masyarakat di Indonesia. Dalam rangka mewujudkan hal tersebut, Perseroan memiliki enam strategi pembenahan utama pada tahun 2021, yaitu:

Inovasi Product and Service Development

Strategi ini sebagai bentuk respon Perseroan terhadap situasi pandemi COVID-19 dan persiapan kebutuhan pemeriksaan kesehatan pasca COVID-19 demi memberikan layanan prima kepada pasien dengan berubahnya gaya hidup higienis dan pola konsumsi dengan preferensi kesehatan.

Restrukturisasi Organisasi

Strategi ini bertujuan menambahkan dan memenuhi fungsi organisasi untuk menjaga kualitas, meningkatkan kinerja dan pelayanan kepada *customer*.

Penguatan Sistem Layanan Digital

Strategi yang bertujuan untuk mempermudah dan efisiensi dalam pelayanan sebagai *supporting* yang mengedepankan sistem digital dan *cashless*.

Sinergi dengan Stakeholder

Strategi ini bertujuan untuk menjalin dan menjaga kerja sama dengan instansi pemerintahan, perusahaan BUMN dan instansi swasta secara menyeluruh.

Quality Assurance Officer

Strategi dalam memastikan kualitas mutu dan standar layanan di seluruh *site* KFD.

TANTANGAN PERSEROAN

Pandemi COVID-19 di tahun 2021 memberikan pengaruh besar terhadap bisnis dunia dan tidak hanya berdampak pada bisnis Kesehatan, tapi juga krisis ekonomi. Kondisi seperti ini negara Indonesia bahkan dunia harus bisa beradaptasi dan berinovasi sebagai upaya normalisasi perubahan-perubahan yang terjadi di kehidupan masyarakat dan bisnis, serta melakukan berbagai penanganan pandemi COVID-19. Perekonomian Indonesia terlihat membaik pada awal tahun 2021, didukung oleh pelonggaran pembatasan mobilitas untuk menahan penyebaran pandemi, sentiment positif atas dimulainya program vaksinasi dan stimulus-stimulus diberbagai sektor ekonomi. Puncaknya kembali ketika Indonesia mengalami gelombang pandemi COVID-19 Varian Delta pada bulan Juli 2021, dan pemerintah mengambil

and Services experienced the highest growth of 29.83%.

STRATEGIC POLICIES

Kimia Farma Diagnostika has policies aiming to improve service quality and sustainable growth of the Company in line with the needs of public health services. With the goal of becoming a professional, reputable Health Service company and able to provide health service solutions for all people in Indonesia. In order to realize this, the Company has six main improvement strategies in 2021, namely:

Product Innovation and Service Development

This strategy is a form of the Company's response to the COVID-19 pandemic situation and preparation for the need for post-COVID-19 health checks in order to provide excellent service to patients by changing hygienic lifestyles and consumption patterns with health preferences.

Organizational Restructuring

This strategy aims to add and fulfill organizational functions to maintain quality, improve performance and service to customers.

Digital Service System Strengthening

A strategy that aims to make it easier and more efficient in services as supporting that prioritize digital and cashless systems.

Synergy with Stakeholders

This strategy aims to establish and maintain cooperation with government agencies, state-owned enterprises and private institutions.

Quality Assurance Officer

A strategy to ensure quality and service standards at all KFD sites.

CHALLENGES FACED

The COVID-19 pandemic in 2021 has had major impact on global businesses, not only on the health business, but also led to an economic crisis. In the midst of such conditions, Indonesia and the world as a whole must be able to adapt and innovate as an effort to normalize the changes that occur in people's and business lives, as well as carry out the COVID-19 pandemic handlings. The Indonesian economy was improving in early 2021, supported by the easing of mobility restrictions to contain the spread of the pandemic, positive sentiment over the start of vaccination program and stimuli in various economic sectors. Afterward, Indonesia experienced a wave of the Delta Variant COVID-19 pandemic in July 2021, and the government took action to re-implement the policy of tightening the Enforcement of



tindakan untuk kembali menerapkan kebijakan memperketat Pemberlakuan Pembatasan Kegiatan Masyarakat (PPKM).

Segala kondisi tersebut menyebabkan tantangan tersendiri yang harus dihadapi Perseroan, di antaranya meningkatnya kembali pasien COVID-19, secara cepat harus menghadapi dan membantu pemerintah dalam menangani pasien kasus COVID-19, sulitnya mencari tenaga medis. Namun, memasuki tahun kedua pandemi, kemampuan Perseroan dalam beradaptasi di tengah kondisi pandemi semakin membaik. Pola kerja yang fleksibel, kemampuan digital, infrastruktur, dan prosedur pencegahan pandemi untuk kebutuhan operasional harian telah terintegrasi secara menyeluruh pada operasional bisnis. Untuk kegiatan operasional pada masa pandemi, sebagian bisnis Kimia Farma Diagnostika telah menghadirkan pelayanan vaksin program Vaksin Gotong Royong (VGR), dibagi menjadi beberapa batch dan dilaksanakan di seluruh kota besar di Indonesia. Inovasi layanan vaksin ini adalah rangka membantu pemerintah dalam mengalokasikan vaksin kepada masyarakat Warga Negara Indonesia (WNI) maupun Warga Negara Asing (WNA) yang berada di Indonesia.

KINERJA PERSEROAN

Seiring dengan membaiknya bisnis proses, pelayanan dan kerja sama yang baik selama 2021, dan didukung dengan kemampuan merespon kondisi pandemi yang semakin baik, seluruh jajaran bisnis Perseroan berhasil mencetak peningkatan kinerja keuangan dan operasional. Perseroan mampu meningkatkan pendapatan bersih sebesar 34,28% dari Rp476,57 miliar di tahun 2020 menjadi Rp639,94 miliar di tahun 2021.

Berdasarkan portofolio Laboratorium Klinik sesuai segmen penjualan mengalami peningkatan yang terbagi menjadi 4 yaitu, pendapatan APS meningkat sebesar 96,88%, pendapatan APD meningkat sebesar 13,58%, pendapatan MCU meningkat sebesar 2,05% dan pendapatan dari hasil Rutin Rujukan meningkat sebesar 75,05%.

Sedangkan dalam portofolio Klinik sesuai segmen penjualan mengalami peningkatan, yaitu pendapatan Tunai Non-Kapitasi sebesar 115,73%, pendapatan Kapitasi meningkat sebesar 47,34% dan pendapatan Kredit meningkat sebesar 258,16%.

Adapun untuk mencapai implementasi GCG yang dipersyaratkan oleh SK-16/S.MBU/2012 tentang Indikator/Parameter Penilaian dan Evaluasi Atas Penerapan Tata Kelola Perusahaan yang baik, Perseroan telah melakukan Implementasi GCG yang sesuai dengan prinsip-prinsipnya, dan rencana akan dilakukan evaluasi *self assessment* GCG pada tahun 2022 sebagai alat ukur kekuatan dan kelemahan yang selanjutnya akan dilakukan perbaikan-perbaikan.

Restrictions on Community Activities (PPKM).

These conditions resulted in challenges that must be faced by the Company, including the re-increasing number of COVID-19 patients, having to quickly deal with and assist the government in dealing with COVID-19 patients, and the difficulty of finding medical personnel. However, entering the second year of the pandemic, the Company's ability to adapt amid the pandemic was getting better. Flexible working patterns, digital capabilities, infrastructure, and pandemic prevention procedures for daily operational needs have been fully integrated into business operations. For operational activities during the pandemic, several Kimia Farma Diagnostika's businesses have provided vaccine services for the Mutual Cooperation Vaccine (VGR) program, divided into several batches and implemented in all major cities in Indonesia. This vaccine service innovation aimed to assist the government in allocating vaccines to Indonesian citizens (WNI) and foreign citizens (WNA) in Indonesia.

COMPANY PERFORMANCE

Along with improving business processes, services and good cooperation during 2021, and supported by better ability to respond to pandemic conditions, all levels of the Company's business managed to improve in financial and operational performance. The Company was able to increase its net revenue by 34.28% from Rp476.57 billion in 2020 to Rp639.94 billion in 2021.

The Clinical Laboratory portfolio according to the sales segment experienced an increase which was divided into 4, namely, APS revenue increased by 96.88%, PPE revenue increased by 13.58%, MCU revenue increased by 2.05% and revenue from Routine Referrals increased by 75.05%.

Meanwhile, the Clinic portfolio according to sales segment experienced an increase, namely Non-Capitation Cash revenue increased by 115.73%, Capitation revenue increased by 47.34% and Credit increased by 258.16%.

Meanwhile, to achieve the implementation of GCG as required by SK-16/S.MBU/2012 on Indicators/Parameters of Assessment and Evaluation of Good Corporate Governance Implementation, the Company has implemented GCG in accordance with its principles, and GCG self-assessment is planned to be conducted in 2022 as a measuring tool for strengths and weaknesses which will then be made improvements.



PROSPEK USAHA KFD 2022

Selama tahun 2021, perseroan proaktif dan sangat kontributif terhadap upaya penanggulangan pandemi COVID-19 nasional. Sebagai BUMN yang memiliki portofolio layanan kesehatan diagnostik, menyelenggarakan *screening* COVID-19 test menjadi *seasonal revenue stream* di tahun 2021. Seiring dengan langkah kebijakan pemerintah untuk percepatan vaksinasi masyarakat untuk pencapaian *herd immunity* nasional dengan pelonggaran pembatasan kegiatan aktivitas masyarakat. Maka KFD mempersiapkan *switching strategy* COVID-19 related dan *new revenue stream* untuk merespon *new behavior consumption* pelanggan terhadap kebutuhan layanan kesehatan. Grand Strategi perseroan untuk menyambut tahun 2022 meliputi:

Intensification and Extensification Existing Revenue Stream

Optimalisasi layanan klinik dan laboratorium medis melalui *site standardization*, vaksinasi, *sampling station*, Laboratorium Pusat Rujukan Nasional, *Pricing Strategy* dan *Equipment Utilization*.

Healthcare Ecosystem Partnership

Kerja sama dengan ekosistem layanan kesehatan di Indonesia diantaranya IHC, BPJS Kesehatan, Mandiri Inhealth, Klinik, Rumah Sakit, dan Puskesmas sebagai sinergi layanan Kesehatan sehingga memberikan *end to end customer journey* di KFD.

Acquisition & Joint Operation

Strategi perusahaan untuk menambah jumlah layanan dan *coverage area* melalui kerja sama kemitraan. Sekaligus menambah portofolio bisnis dari *experienced partner* di bidang kesehatan potensial.

Expanding Clinics Service

Melakukan *refocusing* klinik ke klinik utama dengan layanan dokter spesialis dengan mengikuti skema rujukan berjenjang sebagai *referral* dari klinik pratama sebagai fasilitas kesehatan tingkat pratama ke fasilitas kesehatan tingkat lanjut seperti klinik utama dan Rumah Sakit.

New Revenue Stream: Homecare & Telemarketing

Merupakan strategi pemanfaatan basis pelanggan perseroan melalui *online channel* dengan memberikan pelayanan kesehatan langsung ke lokasi pasien dengan tenaga profesional tanpa harus datang ke fasilitas kesehatan. Layanan yang diberikan diantaranya konsultasi dokter, vaksinasi, rawat luka, *baby spa*, swab antigen/PCR dan sebagainya.

KFD 2022 BUSINESS OUTLOOK

Throughout 2021, the company was proactive and highly contributive to the national COVID-19 pandemic handling efforts. As an SOE that has a portfolio of diagnostic health services, holding the COVID-19 tests screening became the seasonal revenue stream in 2021. In line with government policy measures to accelerate community vaccinations in order to achieve national herd immunity by easing restrictions on people activities. To that end, KFD prepared COVID-19 related switching strategy and new revenue stream to respond to the new consumption behavior of customers for health service needs. The Company's Grand Strategy to welcome 2022 includes:

Intensification and Extensification of Existing Revenue Stream

Optimizing clinical services and medical laboratories through site standardization, vaccination, sampling station, National Referral Center Laboratory, Pricing Strategy and Equipment Utilization.

Healthcare Ecosystem Partnership

Cooperation with the health service ecosystem in Indonesia including IHC, BPJS Health, Mandiri Inhealth, Clinics, Hospitals, and Community Health Centers as a synergy in Health services so as to provide an end-to-end customer journey at KFD.

Acquisition & Joint Operation

The Company's strategy is to increase the number of services and coverage areas through partnerships. At the same time adding the business portfolio of experienced partners in potential health sector.

Expanding Clinics Service

Refocusing the clinic to the main clinic with specialist doctor services by following the tiered referral scheme as a referral from the first clinic as a primary level health facility to advanced health facilities such as the main clinic and hospital.

New Revenue Stream: Homecare & Telemarketing

A strategy to utilize the Company's customer base through online channels by providing health services directly to the patient's location with professional staff without having to come to health facilities. The services provided include doctor consultation, vaccination, wound care, baby spa, antigen/PCR swab and others.



KOMPOSISI DIREKSI

Pada tahun 2021 terjadi 3 kali perubahan susunan Direksi Perseroan. Perubahan pertama, Direktur Utama dan Direktur Keuangan, Sumber Daya Manusia dan Umum berakhir jabatan dan sebagaimana dinyatakan dalam Akta Pernyataan Keputusan Rapat PT Kimia Farma Diagnostika pada Nomor 18, tanggal 17 Mei 2021, yang dibuat di hadapan Ida Farida, S.H., Notaris di Jakarta, sehingga susunan Direksi Perseroan menjadi sebagai berikut:

Agus Chandra	Plt Direktur Utama Acting President Director
Abdul Azis	Plt Direksi Acting Director

Perubahan kedua, Direktur Utama dan Direktur Keuangan, Sumber Daya Manusia dan Umum berakhir jabatan dan sebagaimana dinyatakan dalam Akta Pernyataan Keputusan Rapat PT Kimia Farma Diagnostika pada Nomor 8, tanggal 03 November 2021, yang dibuat di hadapan Dini Lastari Siburian, S.H., Notaris di Jakarta, sehingga susunan Direksi Perseroan menjadi sebagai berikut:

Ardhy Nugrahanto Wokas	Direktur Utama President Director
Muhammad Yushar	Direktur Keuangan, Sumber Daya Manusia & Umum Director of Finance, Human Capital & General Affairs
Winastanto Wibowo	Direktur Operasional Director of Operations

PENUTUP

Demikian laporan pelaksanaan jalannya kepengurusan Perseroan di tahun 2021. Direksi menyampaikan terima kasih kepada para pemegang saham atas dukungan dan kepercayaan yang terus diberikan kepada Perseroan selama ini. Kepada Dewan Komisaris, Direksi mengucapkan terima kasih atas pengawasan dan pemberian nasihat yang diberikan sepanjang tahun 2021. Apresiasi dan terima kasih juga disampaikan kepada para karyawan yang telah memberikan segala daya upaya dari kerja keras, komitmen, dedikasi, dan tanggungjawab yang sudah dijalankan untuk menghadapi kondisi usaha yang penuh dinamika.

Direksi memberikan apresiasi kepada para mitra usaha dan pelanggan yang tetap setia dengan Perseroan atas kepercayaan, kerja sama dan loyalitas yang tak terhenti sampai saat ini.

BOARD OF DIRECTORS COMPOSITION

In 2021, the composition of the Company's Board of Directors has been changed for 3 times. The first change, President Director and Director of Finance, Human Capital and General Affairs ended their tenure as stated in the Deed of Statement of Meeting Resolutions of PT Kimia Farma Diagnostika No. 18, May 17, 2021, drawn up before Ida Farida, S.H., Notary in Jakarta, hence the composition of the Company's Board of Directors is as follows;

The second change, President Director and Director of Finance, Human Capital and General Affairs ended their tenure as stated in the Deed of Statement of Meeting Resolutions of PT Kimia Farma Diagnostika Number 8, dated November 3, 2021, drawn up before Dini Lastari Siburian, S.H., Notary in Jakarta, hence the composition of the Company's Board of Directors is as follows;

CLOSING REMARKS

As closing remarks, this is the end of our report on the management of the Company in 2021. Board of Directors would like to express a gratitude to shareholders for the continued support and trust given to the Company until now. The same expression also goes to Board of Commissioners, for the supervision and advice provided throughout 2021. Appreciation and gratitude are also conveyed to employees who have given all their efforts of hard work, commitment, dedication, and responsibility to deal with the dynamic business conditions.

Board of Directors would like to give an appreciation to our business partners and customers who remain loyal to the Company for their unwavering trust, cooperation and loyalty to date.



Selanjutnya, Direksi akan tetap berkomitmen untuk memberikan yang terbaik bagi Perseroan. Semoga Kimia Farma Diagnostika akan menjadi Laboratorium Klinik yang berkinerja unggul dan menjadi pilihan masyarakat Indonesia. Direksi mohon do'a dan dukungan agar perseroan selalu dapat meraih kinerja yang semakin baik dari tahun ke tahun mendatang. Direksi juga memohon rahmat dan ridho dari Allah SWT, semoga kita semua senantiasa berada dalam lindungan dan rahmat-Nya.

Furthermore, Board of Directors will remain committed to providing the best for the Company. Hopefully Kimia Farma Diagnostika will become a Clinical Laboratory with superior performance and the top-of-mind of the Indonesian people. Board of Directors would like to request continuing prayers and support, so that the Company can always achieve better performance from year to year. Board of Directors would also like to ask for mercy and blessing from Allah SWT, and may we all always be in His protection and grace.

Jakarta, 23 Mei 2022
Atas Nama Direksi PT Kimia Farma Diagnostika
Jakarta, May 23, 2022
On behalf of the Board of Directors of PT Kimia Farma Diagnostika

**drg. ARDHY NUGRAHANTO WOKAS,
MSc PH., MSc HM., Ph.D., DIC., MSCO.**
Direktur Utama
President Director



SURAT PERNYATAAN ANGGOTA- ANGGOTA DEWAN KOMISARIS DAN DIREKSI TENTANG TANGGUNG JAWAB LAPORAN TAHUNAN 2021

STATEMENT LETTER OF MEMBERS OF THE BOARD OF COMMISSIONERS
AND BOARD OF DIRECTORS CONCERNING RESPONSIBILITY FOR THE
2021 ANNUAL REPORT

Surat Pernyataan Anggota Dewan Komisaris dan Direksi tentang Tanggung Jawab atas Laporan Tahunan PT Kimia Farma Diagnostika tahun 2021.

Statement Letter of Members of the Board of Commissioners and Board of Directors regarding the Responsibility for the 2021 Annual Report of PT Kimia Farma Diagnostika.

Kami, yang bertanda tangan di bawah ini, menyatakan bahwa semua informasi dalam Laporan Tahunan PT Kimia Farma Diagnostika tahun 2021 telah dimuat secara lengkap dan bertanggung jawab penuh atas kebenaran isi Laporan Tahunan Perusahaan.

We, the undersigned, declare that all information in the 2021 Annual Report of PT Kimia Farma Diagnostika has been presented in its entirety and we are fully responsible for the accuracy of the contents of the Company's Annual Report.

Demikian pernyataan ini dibuat dengan sebenarnya.

This statement was made with actual.

Jakarta, 23 Mei 2022
Jakarta, May 23, 2022

Dewan Komisaris
Board of Commissioners

Ir. RETNO SUMEKAR, M.Sc
Komisaris Utama
President Commissioner

Dr. dr. ANDANI EKA PUTRA, M.Sc
Komisaris
Commissioner

Direksi
Board of Directors

**drg. ARDHY NUGRAHANTO WOKAS,
MSc PH., MSc HM., Ph.D., DIC., MSCO.**

Direktur Utama
President Director

MUHAMMAD YUSHAR, S.E, Ak.
Direktur Keuangan Sumber Daya Manusia & Umum
Director of Finance, Human Capital & General Affairs

apt. WINASTANTO WIBOWO, S.Farm
Direktur Operasional
Director of Operations





PROFIL PERUSAHAAN

COMPANY PROFILE

2021 Laporan Tahunan
Annual report



DATA PERUSAHAAN

COMPANY DATA



PT Kimia Farma Diagnostika adalah Anak Perusahaan PT Kimia Farma Apotek dan sebagai bagian tidak terpisahkan dari PT Kimia Farma Tbk yang merupakan Badan Usaha Milik Negara. Unit usaha Entitas PT Kimia Farma Diagnostika saat ini mempunyai Laboratorium Klinik sebanyak 72 Laboratorium Klinik dan 406 Klinik yang tersebar di seluruh Indonesia.

PT Kimia Farma Diagnostika is a Subsidiary of PT Kimia Farma Apotek and as an inseparable part of PT Kimia Farma Tbk which is a State-Owned Enterprise. The business unit, PT Kimia Farma Diagnostika, currently has 72 clinical laboratories and 406 clinics spread throughout Indonesia.

	NAMA PERUSAHAAN PT KIMIA FARMA DIAGNOSTIKA	COMPANY NAME PT KIMIA FARMA DIAGNOSTIKA
	ALAMAT KANTOR PUSAT Graha Apic, Jl. Talang Betutu No.5, RT.11/RW.20, Kb. Melati, Kecamatan Tanah Abang, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10230, Indonesia	HEAD OFFICE ADDRESS <i>Graha Apic, Jl. Talang Betutu No.5, RT.11/RW.20, Kb. Melati, Tanah Abang District, Central Jakarta City, Special Capital Region of Jakarta 10230, Indonesia</i>
	MEDIA SOSIAL SOCIAL MEDIA @ Website : labkimiafarma.co.id @ Instagram : @KimiaFarma.ind, @kimiafarmamobile.id	
	TANGGAL PENDIRIAN 2 Desember 2008	DATE OF ESTABLISHMENT December 2, 2008
	KEGIATAN USAHA Pelayanan dan Penyelenggaraan Kesehatan	BUSINESS ACTIVITIES <i>Health Services and Management</i>
	MODAL DASAR Rp250.000.000.000 (Dua Ratus Lima Puluh Juta Rupiah)	AUTHORIZED CAPITAL <i>Rp250,000,000,000 (Two Hundred and Fifty Million Rupiah)</i>
	KEPEMILIKAN <ul style="list-style-type: none"> PT. Kimia Farma Apotek (Pemegang Saham Mayoritas) Yayasan Kesejahteraan Keluarga Kimia Farma 	OWNERSHIP <ul style="list-style-type: none"> <i>PT. Kimia Farma Apotek (Major Shareholder)</i> <i>Yayasan Kesejahteraan Keluarga Kimia Farma</i>



SEKILAS PERUSAHAAN COMPANY OVERVIEW

Untuk memperkuat usaha dari PT Kimia Farma Apotek, dibentuklah anak perusahaan yaitu PT Kimia Farma Diagnostika (KFD) atau lebih dikenal dengan Labklinik KF yang menyelenggarakan kegiatan usaha Perseroan di bidang laboratorium klinik. Dengan demikian posisi PT Kimia Farma Apotek saat ini sebagai *Healthcare Provider Company*, suatu perusahaan jaringan layanan kesehatan terintegrasi, terbesar dan menjadi *market leader* ritel farmasi di Indonesia.

Di tahun 2021 untuk penguatan bisnis laboratorium klinik, kegiatan usaha klinik diintegrasikan menjadi kegiatan usaha baru Perseroan KFD. Hingga akhir tahun 2021, KFD memiliki 478 *outlet* yang tersebar di seluruh Indonesia yang terdiri dari 72 *outlet* laboratorium klinik dan 406 *outlet* klinik.

To strengthen the business of PT Kimia Farma Apotek, a subsidiary company was formed, namely PT Kimia Farma Diagnostika (KFD) or better known as Labklinik KF which organizes the Company's business activities in clinical laboratories. Thus, the current position of PT Kimia Farma Apotek is as a *Healthcare Provider Company*, the largest integrated health service network company, and the market leader of pharmaceutical retail in Indonesia.

In 2021, in order to strengthen the clinical laboratory business, the clinical business activities were integrated into a new business activity for KFD. Until the end of 2021, KFD has 478 outlets spread throughout Indonesia, consisting of 72 clinical laboratory outlets and 406 clinic outlets.

BIDANG USAHA DAN WILAYAH OPERASIONAL LINE OF BUSINESS AND OPERATIONAL AREA

Hingga akhir tahun 2021, KFD telah menjangkau 136 Kabupaten/Kota di 34 Provinsi di seluruh Indonesia dengan total 478 jejaring *outlet* yang terdiri dari 72 lab klinik di antaranya ada 4 *flagship* lab klinik dan lab kerja sama rumah sakit, 24 dokter praktik perorangan, 390 klinik pratama, 16 klinik utama yang di antaranya merupakan Klinik Hemodialisa Kimia Farma, yaitu klinik spesialisik yang melayani terapi cuci darah di luar tubuh dan Oka mata.

Platform Digital Kimia Farma seiring perkembangan zaman di era digitalisasi, Perseroan mengikuti tren perkembangan teknologi dalam meningkatkan layanan bagi pelanggan, Kimia Farma telah memiliki *platform* digital "KF Mobile" untuk sistem pendaftaran dan pembayaran *online* bagi pelanggan Kimia Farma. Layanan pendaftaran dan pembayaran *online* ini membantu pelanggan yang akan melakukan pemeriksaan kesehatan di Laboratorium Klinik Kimia Farma ataupun Klinik Kimia Farma, sehingga tidak perlu lagi mengantri dan melakukan pembayaran di *outlet*.

Melalui layanan ini pelanggan dapat dengan mudah mendaftarkan diri, memilih jenis pemeriksaan yang diinginkan, menentukan lokasi pemeriksaan, dan pembayaran dengan cara yang diinginkan. Sistem Pendaftaran dan Pembayaran *online* ini dapat diakses melalui telepon genggam. Untuk informasi seputar fasilitas dan layanan produk, dapat diakses melalui *website* labkimiafarma.co.id, *e-mail* marketingpusat@labkimiafarma.co.id, sosial media seperti Instagram, dan kontak KFD (+6221) 3857245/ (Whatsapp) +62 821 2399 9942.

Until the end of 2021, KFD has reached 136 regencies/cities in 34 provinces throughout Indonesia with a total of 478 network outlets consisting of 72 clinical labs of which there are 4 flagship clinical labs and hospital collaboration labs, 24 general practitioners, 390 primary care clinics, 16 main clinics include Kimia Farma Hemodialysis Clinic, which is a specialist clinic that provides dialysis therapy outside the body and eye surgery.


Kimia Farma Digital Platform Along with the times in the digitalization era, the Company follows the trend of technological developments to improve services for its customers. Kimia Farma already has a digital platform "KF Mobile" for online registration and payment systems for Kimia Farma customers. This online registration and payment service helps customers that will do health checks at Kimia Farma Clinical Laboratory or Kimia Farma Clinic, in which they no longer need to queue and make payments at the outlets.

Through this service, customers can easily register themselves, choose the type of examination, determine the location, and pay in the desired way. This online registration and payment system can be accessed via mobile phones. While information about product facilities and services can be accessed through the website labkimiafarma.co.id, e-mail marketingpusat@labkimiafarma.co.id, social media such as Instagram, and contact KFD (+6221) 3857245/ (Whatsapp) +62 821 2399 9942.



STRUKTUR ORGANISASI

ORGANIZATIONAL STRUCTURE





UNIT SATUAN PENGAWASAN
INTERNAL
INTERNAL AUDIT UNIT

DIREKTORAT OPERASIONAL
DIRECTORATE OF FINANCE, HC
& RISK MANAGEMENT

UNIT BISNIS
BUSINESS UNIT

UNIT QUALITY
MANAGEMENT
QUALITY
MANAGEMENT UNIT

UNIT OPERATIONAL
& SERVICE
OPERATIONAL &
SERVICE UNIT

UNIT MARKETING &
NATIONAL SALES
MARKETING &
NATIONAL SALES UNIT

UNIT LAB KHUSUS
SPECIAL LAB UNIT

Direktur Utama
President Director

Direktur
Directors

- Direksi
Directors
- Manager
Manager
- Fungsional
Functional
- Asman
Assistant Manager
- Unit Bisnis
Business unit
- Supervisor
Supervisor



VISI, MISI, BUDAYA, DAN NILAI-NILAI INTI PERUSAHAAN

VISION, MISSION, AND CORPORATE VALUES



VISI | VISION

Menjadi penyedia layanan kesehatan yang terpadu, terbaik, terpercaya, dan terbesar di Indonesia.

An integrated, best, trusted, and largest health service provider in Indonesia.



MISI | MISSION

- | | |
|--|--|
| <ol style="list-style-type: none"> 1. Membangun AKHLAK SDM terus menerus dan berkesinambungan 2. Membangun jejaring layanan kesehatan yang berkualitas dan terintegrasi secara nasional 3. Membangun sinergi dengan Kimia Farma Group dan BUMN dalam penyediaan layanan Kesehatan yang lengkap dan terintegrasi (<i>One Stop Healthcare Solution</i>) 4. Meningkatkan citra dan relasi yang baik dengan seluruh <i>stakeholder</i> | <ol style="list-style-type: none"> 1. Build Human Capital with AKHLAK values in a continuous and sustainable manner 2. Build a high quality and nationally integrated network of health services 3. Build synergy with Kimia Farma Group and SOEs in providing complete and integrated Health services (<i>One Stop Healthcare Solution</i>) 4. Improve corporate image and good relations with all stakeholders |
|--|--|









BUDAYA PERUSAHAAN | CORPORATE VALUE

Berdasarkan Surat Edaran KBUMN PER.06/MBU/07/2020 tanggal 1 Juli 2020 tentang Nilai-Nilai Utama (*Core Values*) Sumber Daya Manusia Badan Usaha Milik Negara, maka Perseroan menetapkan AKHLAK sebagai budaya kerja (*core values*) Kimia Farma Grup. Adapun akronim dari *core values* AKHLAK yaitu Amanah, Kompeten, Harmonis, Loyal, Adaptif, dan Kolaboratif yang dijadikan sebagai identitas dan perekat budaya kerja yang mendukung peningkatan kinerja secara berkelanjutan di setiap BUMN.

Based on the Circular Letter of Ministry of SOE PER.06/MBU/07/2020 dated July 1, 2020 regarding the Core Values of Human Capital of State-Owned Enterprises, the Company has determined AKHLAK as the core values of Kimia Farma Group. The acronyms for AKHLAK core values are Trustworthy, Competent, Harmonious, Loyal, Adaptive and Collaborative which serve as identity and work culture adhesives that support continuous performance improvement in each SOE.



	<p>AMANAH</p> <p>Memegang teguh kepercayaan yang diberikan. Panduan perilaku:</p> <ol style="list-style-type: none"> Berperilaku dan bertindak selaras dengan perkataan. Menjadi seseorang yang dapat dipercaya dan bertanggung jawab. Bertindak jujur dan berpegang teguh kepada nilai moral dan etika secara konsisten. 	<p>TRUST</p> <p>Keep on learning and developing capabilities. Behavior guidelines:</p> <ol style="list-style-type: none"> Behave and act following words. Become someone who can be trusted and responsible. Act honestly and consistently uphold moral and ethical values.
	<p>KOMPETEN</p> <p>Terus belajar dan mengembangkan kapabilitas. Panduan perilaku:</p> <ol style="list-style-type: none"> Terus menerus meningkatkan kemampuan/kompetensi agar selalu mutakhir. Selalu dapat diandalkan dengan memberikan kinerja terbaik. Menghasilkan kinerja dan prestasi yang memuaskan. 	<p>COMPETENT</p> <p>Continue to learn and develop capabilities Behavioral guidelines:</p> <ol style="list-style-type: none"> Continuously improve abilities/competencies to keep sophisticated. Always reliable by giving the best performance. Produce satisfactory performance and achievements.
	<p>HARMONIS</p> <p>Saling peduli dan menghargai perbedaan. Panduan perilaku:</p> <ol style="list-style-type: none"> Berperilaku saling membantu dan mendukung sesama insan organisasi maupun masyarakat. Selalu menghargai pendapat, ide, atau gagasan orang lain. Menghargai kontribusi setiap orang dari berbagai latar belakang. 	<p>HARMONIOUS</p> <p>Caring for each other and respecting differences Behavioral guidelines:</p> <ol style="list-style-type: none"> Behave to help and support each other in the organization and society. Always respect other people's opinions, ideas, or concepts. Appreciate the contribution of everyone from various backgrounds.
	<p>LOYAL</p> <p>Berdedikasi dan mengutamakan kepentingan bangsa negara. Panduan perilaku:</p> <ol style="list-style-type: none"> Menunjukkan komitmen yang kuat untuk mencapai tujuan. Bersedia berkontribusi lebih dan rela berkorban dalam mencapai tujuan. Menunjukkan kepatuhan kepada organisasi dan negara. 	<p>LOYAL</p> <p>Dedicating and prioritizing the interests of the nation and state Behavioral guidelines:</p> <ol style="list-style-type: none"> Show strong commitments to achieving goals. Willing to contribute more and sacrifice in achieving goals. Demonstrate compliance with the organization and the country.
	<p>ADAPTIF</p> <p>Terus berinovasi dan antusias dalam menggerakkan ataupun menghadapi perubahan. Panduan perilaku:</p> <ol style="list-style-type: none"> Melakukan inovasi secara konsisten untuk menghasilkan yang lebih baik. Terbuka terhadap perubahan, bergerak lincah, cepat dan aktif dalam setiap perubahan untuk menjadi lebih baik. Bertindak proaktif dalam menggerakkan perubahan. 	<p>ADAPTIVE</p> <p>Continue to innovate and be enthusiastic in driving or facing change Behavioral guidelines:</p> <ol style="list-style-type: none"> To consistently innovate to produce better. Open to change, move agile, fast, and active in every change for the better. Act proactively in driving change.
	<p>KOLABORATIF</p> <p>Membangun kerja sama yang sinergis. Panduan perilaku:</p> <ol style="list-style-type: none"> Terbuka bekerja sama dengan berbagai pihak. Mendorong terjadinya sinergi untuk mendapatkan manfaat dan nilai tambah. Bersinergi untuk mencapai tujuan bersama. 	<p>COLLABORATIVE</p> <p>Building synergistic cooperation Behavioral guidelines:</p> <ol style="list-style-type: none"> Open to cooperate with various parties. Encourage synergy to get benefits and added value. Synergize to achieve common goals.



MAKNA LOGO

DEFINITION OF LOGO



LOGO PERUSAHAAN

Lingkaran bulat dengan *cardiogram*: lingkaran, adalah sebuah kebulatan tekad Perusahaan dan seluruh karyawan untuk memajukan Perusahaan. *Cardiogram* mencerminkan Kualitas Hidup dan kesehatan Jantung Manusia, sejalan dengan Visi Perusahaan menjadi jaringan pelayanan laboratorium klinik terbaik di Indonesia untuk kehidupan yang lebih sehat dengan *tagline Quality for Healthier Life*.

KOMBINASI WARNA ORANGE DAN BIRU

Warna *orange* berarti semangat dan warna biru berarti keabadian. Harmonisasi antara kedua warna tersebut menjadi satu makna yaitu semangat tinggi dan pantang menyerah.

Tanda centang, berarti penunjang diagnosa yang akurat dan teliti serta kepastian waktu sebagai hasil dan penerapan sistem mutu (ISO 15189 dan KALK).

Matahari selalu terbit dari timur dan tenggelam dari arah barat secara teratur dan terus menerus memiliki makna adanya komitmen dan konsistensi dan menjalankan segala tugas yang diemban oleh Kimia Farma dalam bidang farmasi dan kesehatan. Selain itu Matahari sebagai sumber energi bagi kehidupan dan kimia farma baru memposisikan dirinya sebagai sumber energi bagi kesehatan masyarakat.

COMPANY LOGO

A round circle with a *cardiogram*: a circle represents the determination of the Company and all employees to advance the Company. *Cardiogram* reflects the Quality of Life and the Health of Human Heart, in line with the Company's vision to become the best clinical laboratory service network in Indonesia for a healthier life with the *tagline Quality for Healthier Life*.

ORANGE AND BLUE COLOR COMBINATION

The color orange means passion and blue means eternity. Harmonization between the two colors unites into one meaning, high spirits and never give up.

Check mark, means accurate and thorough diagnostic support and time certainty as a result and implementation of the quality system (ISO 15189 and KALK).

The sun always rises from the east and sets from the west in a regular and continuous manner, reflects a commitment and consistency and carrying out all tasks entrusted to Kimia Farma in pharmacy and health business. In addition, the Sun is a source of energy for life and Kimia Farma positions itself as a source of energy for public health.



PROFIL DEWAN KOMISARIS

BOARD OF COMMISSIONERS PROFILE



Ir. RETNO SUMEKAR, M.Sc

KOMISARIS UTAMA
PRESIDENT COMMISSIONER

Periode Jabatan: Mulai Menjabat 16 Maret 2021-Sekarang,
Periode Kedua

Term of Office: Start Serving at March 16, 2021 – Present,
Second Period

Data Pribadi | Personal Data:

Warga Negara Nationality	Indonesia	
Usia Age	62 tahun	62 years old
Kelahiran Birth	Banyuwangi , 17 April 1960	Banyuwangi, April 17, 1960
Domisili Domicile	Jakarta, Indonesia	Jakarta, Indonesia

Riwayat Penunjukan | Appointment History:

Diangkat sebagai Komisaris Utama melalui RUPS Tahunan Tahun Buku 2020 yang telah dilembagakan dalam Akta Pernyataan Keputusan Rapat Umum Pemegang Saham Tahunan PT Kimia Farma Diagnostika No. 27 tanggal 16 Maret 2021 yang dibuat oleh Ida Farida, S.H., Notaris di Jakarta.	Appointed as President Commissioner through the Annual General Meeting of Shareholders for Fiscal Year 2020, as institutionalized in the Deed of Statement of Resolution of Annual General Meeting of Shareholders of PT Kimia Farma Diagnostika No. 27 dated March 16, 2021, drawn up by Ida Farida, S.H., Notary in Jakarta.
--	--

Pendidikan | Education:

<ul style="list-style-type: none"> S2 Kajian Ilmu Lingkungan Universitas Indonesia (2002); Sarjana Teknik Kimia Univ. Pemb. Nasional Veteran (UPN) Jawa Timur (1985). 	<ul style="list-style-type: none"> Master Degree in Environmental Studies, University of Indonesia (2002); Bachelor of Chemical Engineering, University of Pemb. Nasional Veteran (UPN) East Java (1985).
---	---

Riwayat Pekerjaan | Work Experience:

<ul style="list-style-type: none"> Komisaris PT Kimia Farma Diagnostika Periode 2 (2020-Sekarang); Komisaris PT Kimia Farma Diagnostika Periode 1 (2018 – 2020); Direktur Perusahaan Pemula Berbasis Teknologi - Kementerian Riset dan Teknologi (2015 – 2020); Kepala Bidang Pemetaan Perkembangan IKM - Kementerian Riset dan Teknologi (2010 – 2015); Kepala Bidang Perlindungan Kekayaan Intelektual – Kementerian Riset dan Teknologi (2001 – 2010). 	<ul style="list-style-type: none"> Commissioner of PT Kimia Farma Diagnostika, 2nd Period (2020-Present); Commissioner of PT Kimia Farma Diagnostika, 1st Period (2018 – 2020); Director of Technology-Based Startup Company - Ministry of Research and Technology (2015 – 2020); Head of Mapping of Small and Medium Enterprises Development - Ministry of Research and Technology (2010 – 2015); Head of Intellectual Property Protection – Ministry of Research and Technology (2001 – 2010).
--	---

Rangkap Jabatan | Concurrent Positions:

Tidak ada rangkap jabatan.	None.
----------------------------	-------

Hubungan Afiliasi | Affiliate Relationship:

Retno Sumekar tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris lain dan anggota Direksi manapun dengan Pemegang Saham Utama dan Pengendali.	Retno Sumekar has no affiliation with other members of Board of Commissioners, members of Board of Directors, and Major and Controlling Shareholders.
--	---



Dr. dr. ANDANI EKA PUTRA, M.Sc

KOMISARIS
COMMISSIONER

**Periode Jabatan: Mulai Menjabat 16 Maret 2021 – Sekarang,
Periode Pertama**

**Term of Office: Start Serving at March 16, 2021 – Present,
First Period**

Data Pribadi | Personal Data:

Warga Negara Nationality	Indonesia
Usia Age	50 tahun 50 years old
Kelahiran Birth	Terusan 15 Agustus 1972 Terusan, August 15, 1972
Domisili Domicile	Jakarta, Indonesia Jakarta, Indonesia

Riwayat Penunjukan | Appointment History:

Diangkat sebagai Komisaris melalui RUPS Tahunan Tahun Buku 2020 yang telah dilembagakan dalam Akta Pernyataan Keputusan Rapat Umum Pemegang Saham PT Kimia Farma Diagnostika No 27 tanggal 16 Maret 2021 yang dibuat oleh Ida Farida, S.H., Notaris di Jakarta.

Appointed as Commissioner through the Annual GMS for Fiscal Year 2020, as institutionalized in the Deed of Statement of Resolution of General Meeting of Shareholders of PT Kimia Farma Diagnostika No. 27 dated March 16, 2021, drawn up by Ida Farida, S.H., Notary in Jakarta.

Pendidikan | Education:

- S3 Biomedik, FK. UGM (2016);
- S2 Kedokteran Tropis, Jurusan Immunologi dan Molekular Penyakit tropis, FK. UGM (2010);
- S1 Kedokteran Umum, FK. Unand (1997).
- Doctorate in Biomedical, Faculty of Medicine, UGM (2016);
- Master in Tropical Medicine, Department of Immunology and Molecular Diseases of Tropical Medicine, Faculty of Medicine, UGM (2010);
- Bachelor in General Medicine, Faculty of Medicine, Unand (1997).

Riwayat Pekerjaan | Work Experience:

- Tenaga Ahli Kementerian Kesehatan (2021-Sekarang);
- Medical Research Consultant (2020-2021);
- Ketua TTO LPPM Unand (2020-sekarang);
- Ketua Penjaminan Mutu FK Unand (2017-2021);
- Direktur USD, RS Unand (2018-2021);
- Kabid. Pengembangan dan Riset, RS Unand (2017-2018);
- Direktur Klinik Medika Andalas (2015-2017);
- Ketua Tim Teknis Alkes IDB Project (2014-2016);
- Procurement Officer HWS Project (2004-2007);
- Dosen FK Unri (2003-2005);
- Koord Dokter Keluarga PT Suka Fajar (2004-2014);
- Dosen FK Unbrah (2000-2002);
- Kepala UGD RSI Ibnu Sina Padang (1999-2007);
- Dosen (Ked Umum, Biomedik, Kebidanan, S2, dan S3) FK Unand (1999).
- Experts of the Ministry of Health (2021-Present).
- Medical Research Consultant (2020 – 2021);
- Head of TTO LPPM Unand (2020 - present);
- Head of Quality Assurance of Unand Faculty of Medicine (2017-2021);
- USD Director, Unand Hospital (2018-2021);
- Head of Development and Research, Unand Hospital (2017-2018);
- Andalas Medical Clinic Director (2015-2017);
- Head of IDB Project Medical Devices Technical Team (2014-2016);
- Procurement Officer of HWS Project (2004-2007);
- Lecturer at Faculty of Medicine Unri (2003-2005);
- PT Suka Fajar Family Physician Coord (2004-2014);
- Lecturer at Faculty of Medicine Unbrah (2000-2002);
- Head of Emergency Room at RSI Ibnu Sina Padang (1999-2007);
- Lecturer (General Education, Biomedical, Midwifery, Master and Doctoral Degree) at Faculty of Medicine Unand (1999).

Rangkap Jabatan | Concurrent Positions:

Tidak ada rangkap jabatan. None.

Hubungan Afiliasi | Affiliate Relationship:

Dr. dr. Andani Eka Putra, M.Sc. tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris lain dan anggota Direksi manapun dengan Pemegang Saham Utama dan Pengendali.

Dr. dr. Andani Eka Putra, M.Sc. has no affiliation with other members of Board of Commissioners, members of Board of Directors, and Major and Controlling Shareholders.



PROFIL DIREKSI BOARD OF DIRECTORS PROFILE



drg. ARDHY NUGRAHANTO WOKAS, MSc PH., MSc HM., Ph.D., DIC., MSCO.

DIREKTUR UTAMA
PRESIDENT DIRECTOR

Periode Jabatan: Mulai Menjabat 03 November 2021 – Sekarang, Periode Pertama

Term of Office: Start serving at November 03, 2021 – Present, First Period

Data Pribadi | Personal Data:

Warga Negara Nationality	Indonesia	
Usia Age	34 tahun	34 years old
Kelahiran Birth	Geser, 30 April 1988	Geser, April 30, 1988
Domisili Domicile	Jakarta, Indonesia	Jakarta, Indonesia

Riwayat Penunjukan | Appointment History:

Diangkat sebagai Direktur Utama melalui Keputusan Pemegang Saham diluar Rapat pada 02 November 2021 yang telah dilembagakan dalam Akta Pernyataan Keputusan Sirkuler Para Pemegang Saham No. 08 tanggal 03 November 2021 yang dibuat oleh Notaris Dini Lastari Siburian, S.H., Notaris di Jakarta.	Appointed as President Director through Shareholders' Resolution in lieu of Meeting on November 2, 2021, as institutionalized in the Deed of Statement of Shareholders' Circular Resolution No. 08 dated November 03, 2021, made before Notary Dini Lastari Siburian, S.H., Notary in Jakarta.
--	--

Pendidikan | Education:

<ul style="list-style-type: none"> S2 <i>Clinical Services Operation</i> (MSCO), Harvard Medical School University of Harvard, United State (USA) (2021); <i>Fellowship</i> at Harvard University, United State (USA), (2018); Msc + PhD (1+3 YearsTrack) and DIC of <i>Health Policy and Innovation</i>, United Kingdom (UK), (2018). 	<ul style="list-style-type: none"> Master Degree in <i>Clinical Services Operation</i> (MSCO), Harvard Medical School University of Harvard, United State (USA) (2021); <i>Fellowship</i> at Harvard University, United State (USA), (2018); MSc + PhD (1+3 YearsTrack) and DIC of <i>Health Policy and Innovation</i>, United Kingdom (UK), (2018).
---	---

Riwayat Pekerjaan | Work Experience:

<ul style="list-style-type: none"> Direktur Utama PT Kimia Farma Diagnostika (2021-Sekarang); Direktur Utama Siaga Medika Hospital Group (2019-2021); Konsultan Akreditasi Kars RS Buah Hati Ciputat; RSIA Buah Hati Pamulang; RSIA Vitalaya; dan RS Siaga Medika Group (2013-2016); Direktur RSIA and RSU Buah Hati Ciputat (2014-2019). 	<ul style="list-style-type: none"> President Director of PT Kimia Farma Diagnostika (2021-Present); President Director of Siaga Medika Hospital Group (2019-2021) Kars Accreditation Consultant for RSIA Buah Hati Ciputat; RSIA Buah Hati Pamulang; RSIA Vitalaya; and RS Siaga Medika Group (2013-2016); Director of RSIA and RSU Buah Hati Ciputat (2014-2019).
---	--

Rangkap Jabatan | Concurrent Positions:

Tidak ada rangkap jabatan.	None.
----------------------------	-------

Hubungan Afiliasi | Affiliate Relationship:

Ardhy Nugrahanto Wokas tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris lain dan anggota Direksi manapun dengan Pemegang Saham Utama dan Pengendali.	Ardhy Nugrahanto Wokas has no affiliation with other members of Board of Commissioners, members of Board of Directors, and Major and Controlling Shareholders.
---	--



MUHAMMAD YUSHAR, S.E, Ak.

DIREKTUR KEUANGAN SUMBER DAYA MANUSIA & UMUM
DIRECTOR OF FINANCE, HUMAN CAPITAL & GENERAL AFFAIRS

Periode Jabatan: Mulai Menjabat 03 November 2021 – Sekarang, Periode Pertama

Term of Office: Start serving at November 03, 2021 – Present, First Period

Data Pribadi | Personal Data:

Warga Negara Nationality	Indonesia	
Usia Age	43 tahun	43 years old
Kelahiran Birth	Ujung Pandang, 11 Maret 1979	Ujung Pandang, March 11, 1979
Domisili Domicile	Jakarta, Indonesia	Jakarta, Indonesia

Riwayat Penunjukan | Appointment History:

Diangkat sebagai Direktur Keuangan Sumber Daya Manusia Umum melalui RUPS Tahunan Tahun Buku 2021 yang telah dilembagakan dalam Akta Pernyataan Keputusan Sirkuler Para Pemegang Saham PT Kimia Farma Diagnostika No 08 tanggal 03 November 2021 yang dibuat oleh Dini Lastari Siburian, S.H., Notaris di Jakarta Selatan.	Appointed as Director of Finance, Human Resources & General Affairs through the Annual GMS for Fiscal Year 2021, as institutionalized in the Deed of Statement of Shareholders' Circular Resolution of of PT Kimia Farma Diagnostika No.08 dated November 3, 2021, made before Dini Lastari Siburian, S.H., Notary in South Jakarta.
---	--

Pendidikan | Education:

- Sarjana Akuntansi dari Universitas Sumatera Utara Medan (2004).
- Bachelor of Accounting from the University of North Sumatra, Medan (2004).

Riwayat Pekerjaan | Work Experience:

- Direktur Keuangan Sumber Daya Manusia & Umum PT Kimia Farma Diagnostika (2021-Sekarang);
- AVP Tax & Acct Policy PT Bio Farma (Persero), (2020-2021);
- Kepala Bagian Pajak PT Bio Farma (Persero), (2014-2020);
- Kasir PPh PT Bio Farma (Persero), (2010-2014).
- Director of Finance, Human Resources & General Affairs of PT Kimia Farma Diagnostika (2021-Present);
- AVP Tax & Acct Policy of PT Bio Farma (Persero), (2020-2021);
- Head of Tax Section of PT Bio Farma (Persero), (2014-2020);
- PPh Section Head of PT Bio Farma (Persero), (2010-2014).

Rangkap Jabatan | Concurrent Positions:

Tidak ada rangkap jabatan. None.

Hubungan Afiliasi | Affiliate Relationship:

Muhammad Yushar tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris lain dan anggota Direksi manapun dengan Pemegang Saham Utama dan Pengendali. Muhammad Yushar has no affiliation with other members of Board of Commissioners, members of Board of Directors, and Major and Controlling Shareholders.



apt. WINASTANTO WIBOWO, S.Farm

DIREKTUR OPERASIONAL
DIRECTOR OF OPERATIONS

**Periode Jabatan: Mulai Menjabat 03 November 2021-Sekarang,
Periode Pertama**

**Term of Office: Start serving at November 03, 2021-Present,
First Period**

Data Pribadi | Personal Data:

Warga Negara Nationality	Indonesia	
Usia Age	36 tahun	36 years old
Kelahiran Birth	Lamongan, 5 April 1986	Lamongan, April 5, 1986
Domisili Domicile	Jakarta, Indonesia	Jakarta, Indonesia

Riwayat Penunjukan | Appointment History:

Diangkat sebagai Direktur Keuangan Sumber Daya Manusia Umum melalui RUPS Tahunan Tahun Buku 2021 yang telah dilembagakan dalam Akta Pernyataan Keputusan Sirkuler Para Pemegang Saham PT Kimia Farma Diagnostika No 08 tanggal 03 November 2021 yang dibuat oleh Dini Lastari Siburian, S.H., Notaris di Jakarta Selatan.	Appointed as Director of Operations through the Annual GMS for Fiscal Year 2021, as institutionalized in the Deed of Shareholders' Circular Resolution of PT Kimia Farma Diagnostika Deed No. 08 dated November 3, 2021, made before Dini Lastari Siburian, S.H., Notary in South Jakarta.
---	--

Pendidikan | Education:

- Profesi Apoteker, Universitas Airlangga Surabaya (2010);
- Sarjana Farmasi, Universitas Jember (2009).
- Pharmacist Profession, Airlangga University, Surabaya (2010);
- Bachelor of Pharmacy, University of Jember (2009).

Riwayat Pekerjaan | Work Experience:

- Direktur Operasional (2021-Sekarang);
- *Manager* Bisnis PT Kimia Farma Unit Bisnis Manado (2020-2021);
- *Manager* Bisnis PT Kimia Farma Unit Bisnis Nusa Dua (2020-2020);
- *Manager* Bisnis PT Kimia Farma Unit Bisnis Ternate (2018-2020);
- Director of Operations (2021-Present);
- Business Manager of PT Kimia Farma Manado Business Unit (2020-2021);
- Business Manager of PT Kimia Farma Nusa Dua Business Unit (2020-2020);
- Business Manager of PT Kimia Farma Ternate Business Unit (2018-2020).

Rangkap Jabatan | Concurrent Positions:

Tidak ada rangkap jabatan. None.

Hubungan Afiliasi | Affiliate Relationship:

Winastanto Wibowo tidak memiliki hubungan afiliasi dengan anggota Dewan Komisaris lain dan anggota Direksi manapun dengan Pemegang Saham Utama dan Pengendali. Winastanto Wibowo has no affiliation with other members of Board of Commissioners, members of Board of Directors, and Major and Controlling Shareholders.



Ir. RETNO SUMEKAR, M.Sc

KOMISARIS UTAMA
PRESIDENT COMMISSIONER



Dr. dr. ANDANI EKA PUTRA, M.Sc

KOMISARIS
COMMISSIONER



**apt. WINASTANTO
WIBOWO, S.Farm**
DIREKTUR OPERASIONAL
DIRECTOR OF OPERATIONS

**drg. ARDHY
NUGRAHANTO WOKAS,
MSc PH., MSc HM., Ph.D.,
DIC., MSCO.**
DIREKTUR UTAMA
PRESIDENT DIRECTOR

**MUHAMMAD YUSHAR,
S.E, Ak.**
DIREKTUR KEUANGAN SUMBER
DAYA MANUSIA & UMUM
DIRECTOR OF FINANCE, HUMAN
CAPITAL & GENERAL AFFAIRS



PROFIL PEJABAT EKSEKUTIF

EXECUTIVES PROFILE

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 41 Tahun 41 Years Old
Domisili Domicile	: Malang, Jawa Timur, Indonesia Malang, East Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Agustus 2008 August 1, 2008
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Magister Manajemen, Universitas Ciputra Surabaya (2022) • Profesi Apoteker, Universitas Surabaya (2004) • Sarjana Farmasi, Universitas Surabaya (2001) • Master of Management, Ciputra University Surabaya (2022) • Pharmacist Profession, University of Surabaya (2004) • Bachelor of Pharmacy, University of Surabaya (2001)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager Jawa Timur 2 (2021-Sekarang)</i> • <i>Business Manager Klinik Surabaya (2018-2021)</i> • PHM KF 48 Matraman (2017- 2018) • Regional Business Manager East Java 2 (2021-Present) • Business Manager Surabaya Clinic (2018-2021) • PHM KF 48 Matraman (2017- 2018)



Anisa Ika Rahmawati
Regional Business Manager Jawa Timur 2
East Java 2 Regional Business Manager

Menjabat Sejak Served Since	: Agustus 2021 August 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 33 Tahun 33 Years Old
Domisili Domicile	: Bangkinang, Kepulauan Riau, Indonesia Bangkinang, Riau Island, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Januari 2016 January 1, 2016
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Profesi Apoteker, Universitas Ahmad Dahlan (2012-2013) • Sarjana Farmasi, Universitas Muhammadiyah (2008-2012) • Pharmacist Profession, Ahmad Dahlan University (2012-2013) • Bachelor of Pharmacy, Muhammadiyah University (2008-2012)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager KFD Unit Bisnis Sumatera 1 (2021-Sekarang)</i> • <i>Business Manager KFD Unit Bisnis Kalimantan 1 (2021)</i> • <i>Pj Manager KFA Unit Bisnis Klinik Medan (2020)</i> • Business Manager of KFD Sumatra 1 Business Unit (2022-Present) • Business Manager of KFD Kalimantan 1 Business Unit (2021) • Acting Manager of KFD Medan Clinic Business Unit (2020)



Jasmi Harjo
Regional Business Manager Kalimantan 1
Kalimantan 1 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 48 Tahun 48 years old
Domisili Domicile	: Batam, Riau, Indonesia Batam, Riau, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 3 Januari 2005 January 3, 2005
Riwayat Pendidikan Educational Background	: Sarjana Manajemen, STIE YPKP Bandung Bachelor of Management, STIE YPKP Bandung
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Kalimantan 2 (2021-Sekarang) • <i>Business Manager</i> KFD Kalimantan (2018-2020) • <i>Service Manager</i> Lab. Klinik Kimia Farma Batam • <i>Business Manager</i> of Kalimantan 2 (2021-Present) • <i>Business Manager</i> of Kalimantan (2018-2020) • <i>Service Manager</i> Lab. Clinic of Kimia Farma Batam



Framiarta
Regional Business Manager
Kalimantan 2
Kalimantan 2 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 32 Tahun 32 years old
Domisili Domicile	: Makassar, Sulawesi Selatan, Indonesia Makassar, South Sulawesi, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 November 2014 November 1, 2014
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • <i>Profesi Apoteker</i>, Universitas Hasanuddin Makassar (2012-2013) • <i>Sarjana Farmasi</i>, Universitas Hasanuddin (2007-2012) • <i>Bachelor of Pharmacy</i>, Hasanuddin University (2007-2012) • <i>Pharmacist Profession</i>, Hasanuddin University Makassar (2012 -2013)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Kalimantan 3 (2021-Sekarang) • <i>Business Manager</i> Klinik Kimia Farma Manado (2018-2021) • <i>Pharmacy Manager</i> Kimia Farma Pettarani Makassar (2016-2018) • <i>Business Manager</i> of KFD Kalimantan 3 (2021-Present) • <i>Business Manager</i> of Kimia Farma Clinic Manado (2018-2021) • <i>Pharmacy Manager</i> of Kimia Farma Pettarani Makassar (2016-2018)



Apt. Ivan Tarto Hartono Gunawan, S.Si
Regional Business Manager
Kalimantan 3
Kalimantan 3 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 40 Tahun 40 years old
Domisili Domicile	: Makassar, Sulawesi Selatan, Indonesia Makassar, South Sulawesi, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 25 Januari 2007 January 25, 2007
Riwayat Pendidikan Educational Background	: Sarjana Ilmu Komunikasi Fisip, Universitas Hasanuddin Bachelor of Communication Science, Hasanuddin University
Riwayat Pekerjaan Employment History	<ul style="list-style-type: none"> • <i>Business Manager</i> Unit Bisnis Sulawesi 1 (2021-Sekarang) • <i>Business Manager</i> Unit Bisnis Sumalpu • <i>Business Manager</i> of KFD Sulawesi 1 Business Unit (2021-Present) • <i>Business Manager</i> of Sumalpu Business Unit



Andi Dilliana
Regional Business Manager Sulawesi 1
Sulawesi 1 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 29 Tahun 29 years old
Domisili Domicile	: Serang, Banten, Indonesia Serang, Banten, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 22 November 2018 November 22, 2018
Riwayat Pendidikan Educational Background	<ul style="list-style-type: none"> • Profesi Apoteker, Universitas Andalas (2017-2018) • Sarjana Farmasi, Universitas Andalas (2012-2016) • Pharmacist Profession, Andalas University (2017-2018) • Bachelor of Pharmacy, Andalas University (2012-2016)
Riwayat Pekerjaan Employment History	<ul style="list-style-type: none"> • Plt. <i>Regional Business Manager</i> KFD Unit Bisnis Jawa Tengah 2 (2021-Sekarang) • Plt. <i>Regional Business Manager</i> KFD Unit Bisnis Sulawesi 2 (2021) • <i>Service Manager</i> Laboratorium Klinik Kimia Farma Manado (2019-2020) • Acting Regional Business Manager of KFD Central Java 2 Business Unit (2022-Present) • Acting Regional Business Manager of KFD Sulawesi 2 Business Unit (2021-2022) • <i>Service Manager</i> of Kimia Farma Manado Clinical Laboratory (2019-2020)



Maria Clara Chrisantini
Plt. Regional Business Manager Unit Bisnis Jawa Tengah 2
Acting Central Java 2 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 42 Tahun 42 years old
Domisili Domicile	: Bengkulu Selatan, Bengkulu, Indonesia South Bengkulu, Bengkulu, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 6 Maret 2011 March 6, 2011
Riwayat Pendidikan Educational Background	: Sarjana Pertanian, Universitas Lampung Bachelor of Agriculture, Lampung University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Unit Bisnis Sumatera 3 (202-Sekarang) • <i>Business Manager</i> KFD Sumbagsel (2018-2020) • Business Manager of KFD Sumatra 3 Business Unit (202-Present) • Business Manager of KFD Sumbagsel (2018-2020)



Nasihin, S.P
Regional Business Manager
Sumatera 3
Sumatera 3 Regional Business Manager

Menjabat Sejak Served Since	: Agustus 2021 August 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 37 Tahun 37 years old
Domisili Domicile	: Serang, Banten, Indonesia Serang, Banten, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Januari 2010 January 1, 2010
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Profesi Apoteker, Universitas Gadjah Mada (2007-2008) • Sarjana Farmasi, Universitas Ahmad Dahlan (2002-2007) • Pharmacist Profession, Gadjah Mada University (2007-2008) • Bachelor of Pharmacy, Ahmad Dahlan University (2002-2007)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> Banten 1 (2021-Sekarang) • <i>Business Manager</i> KFD Sumatera 4 (2021) • <i>Business Manager</i> KFA • Business Manager Banten 1 (2021-Present) • Business Manager of KFD Sumatera 4 (2021) • Business Manager KFA



Heru Sudomo
Regional Business Manager Banten 1
Banten 1 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 36 Tahun 36 years old
Domisili Domicile	: Batam, Kepulauan Riau, Indonesia Batam, Riau Islands, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 September 2010 September 1, 2010
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Magister Manajemen, Universitas Gadjah Mada • Profesi Apoteker, Universitas Gadjah Mada • Sarjana Farmasi, Universitas Gadjah Mada • Master of Management, Gadjah Mada University • Pharmacist Profession, Gadjah Mada University • Bachelor of Pharmacy, Gadjah Mada University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Sumatera 5 (2021-Sekarang) • <i>Business Manager</i> KFD Klinik Jakarta • <i>Business Manager</i> Klinik Jakarta • Business Manager of KFD Sumatera 5 (2021-Present) • Business Manager of KFD Jakarta Clinic • Business Manager Jakarta Clinic



Anton Dewanto Purnomo
Regional Business Manager
Sumatra 5
Sumatra 5 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 33 Tahun 33 years old
Domisili Domicile	: Bandung, Jawa Barat, Indonesia Bandung, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Maret 2019 March 1, 2019
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Magister Teknologi Farmasi, Universitas Padjdjaran (2014-2016) • Profesi Apoteker, Universitas Padjdjaran (2013-2014) • Sarjana Farmasi, Universitas Padjdjaran (2008-2013) • Master of Pharmaceutical Technology, Padjdjaran University (2014-2016) • Pharmacist Profession, Padjdjaran University (2013-2014) • Bachelor of Pharmacy, Padjdjaran University (2008-2013)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Unit Bisnis Bali Nusra (2021-Sekarang) • <i>Service Manager</i> Laboratorium Klinik Kimia Farma Denpasar Bali, KFD Unit Bisnis Jawa Timur-Bali Nusra (2020) • <i>Service Manager</i> Laboratorium Klinik Kimia Farma Sutomo Semarang, KFD Unit Bisnis Jateng-DIY (2019-2020) • Business Manager of KFD Bali Nusra Business Unit (2021-Present) • Service Manager of Kimia Farma Clinic Laboratory Denpasar Bali, KFD East Java-Bali Nusra Business Unit (2020) • Service Manager of Kimia Farma Clinical Laboratory Sutomo Semarang, KFD Central Java-DIY Business Unit (2019-2020)



Mirani Pertiwi Rahmah
Regional Business Manager Bali Nusra
Bali Nusra Regional Business Manager



Menjabat Sejak Served Since	: Agustus 2021 August 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 36 Tahun 36 years old
Domisili Domicile	: Tangerang, Banten, Indonesia Tangerang, Banten, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Januari 2013 January 1, 2013
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Profesi Apoteker, Universitas Indonesia (2011-2012) • Sarjana Farmasi, UIN Syarif Hidayatullah Jakarta (2005-2009) • Pharmacist Profession, University of Indonesia (2011-2012) • Bachelor of Pharmacy, UIN Syarif Hidayatullah Jakarta (2005-2009)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Jakarta 2 (2021-Sekarang) • <i>Business Manager</i> KFD Banten 1 • <i>PJ Manager</i> Unit Bisnis Pontianak • Business Manager of KFD Jakarta 2 (2021-Present) • Business Manager of KFD Banten 1 • <i>PJ Manager</i> of Pontianak Business Unit



Hidayatul Falah Alatas

Regional Business Manager Jakarta 2
Jakarta 2 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian citizen
Usia Age	: 33 Tahun 33 years old
Domisili Domicile	: Bandung, Jawa Barat, Indonesia Bandung, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: Januari 2013 January 2013
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Magister Management Rumah Sakit, Universitas Pasundan (2019-2022) • Profesi Apoteker, Universitas Padjajaran (2011-2012) • Sarjana Farmasi, Universitas Padjajaran (2007-2011) • Master of Hospital Management, Pasundan University (2019-2022) • Pharmacist Profession, Padjadjaran University (2011-2012) • Bachelor of Pharmacy, Padjadjaran University (2007-2011)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Unit Bisnis Jabar 1 (2021-Sekarang) • <i>Business Manager</i> Kimia Farma Klinik Bandung (2018-2020) • PHM Kimia Farma Universitas Padjajaran (2016-2018) • Business Manager of KFD West Java 1 Business Unit (2021-Present) • Business Manager Kimia Farma Clinic Bandung (2018-2020) • PHM Kimia Farma Padjadjaran University (2016-2018)



Riestya Dwi Permata

Regional Business Manager
Jawa Barat 1
West Java 1 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 30 Tahun 30 years old
Domisili Domicile	: Lampung Utara, Lampung, Indonesia North Lampung, Lampung, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 April 2015 April 1, 2015
Riwayat Pendidikan Educational Background	: Sarjana Ekonomi, IAI Agus Salim Metro Lampung Bachelor of Economics, IAI Agus Salim Metro Lampung
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Jawa Barat 2 (2021-Sekarang) • <i>Service Manager</i> KFD Cilegon (2019-2020) • <i>Marketing</i> KFD Cilegon & Serang (2016-2019) • <i>Business Manager</i> of KFD Kalimantan 2 (2021-Present) • <i>Service Manager</i> of KFD Cilegon (2019-2020) • <i>Marketing</i> of KFD Cilegon & Serang (2016-2019)



Arief Bangsawan Aldo
Plt. Regional Business Manager
Jawa Barat 2
Acting West Java 2 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 34 Tahun 34 years old
Domisili Domicile	: Garut, Jawa Barat, Indonesia Garut, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 11 Januari 2012 January 11, 2012
Riwayat Pendidikan Educational Background	: D-IV Analis Teknologi Laboratorium Medik D-IV Medical Laboratory Technology Analyst
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Plt. Branch Manager</i> Jawa Barat 3 (2021-Sekarang) • <i>Service Manager</i> (2019-2020) • <i>Marketing</i> (2015-2019) • <i>Acting West Java 3 Branch Manager</i> (2021-Present) • <i>Service Manager</i> (2019-2020) • <i>Marketing</i> (2015-2019)



Abi Hakim Al Iman
Plt. Regional Business Manager
Jawa Barat 3
Acting West Java 3 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 49 Tahun 49 years old
Domisili Domicile	: Depok, Jawa Barat, Indonesia Depok, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Januari 2021 January 1, 2021
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Magister Management, Universitas Terbuka (2009-2011) • Profesi Apoteker, Institut Teknologi Bandung (1999-2000) • Sarjana Farmasi, Institut Teknologi Bandung(1992-1997) • Master of Management, University Terbuka (2009-2011) • Pharmacist Profession, Bandung Institute of Technology (1999-2000) • Bachelor of Pharmacy, Bandung Institute of Technology (1992-1997)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Jawa Barat 4 (2021-Sekarang) • <i>Business Manager</i> KFD Jawa Barat 2 • <i>Asisten Manager</i> Klinik PT Kimia Farma Apotek (2014-2018) • Business Manager of KFD West Java 4 (2021-Present) • Business Manager of KFD West Java 2 • Assistant Clinical Manager of PT Kimia Farma Apotek (2014-2018)



Asep Dasuki Suratman
Regional Business Manager
Jawa Barat 4
West Java 4 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 45 Tahun 45 years old
Domisili Domicile	: Depok, Jawa Barat, Indonesia Depok, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Juli 2011 July 1, 2011
Riwayat Pendidikan Educational Background	: Sarjana Kesehatan Masyarakat, Universitas Indonesia (2009) Bachelor of Public Health, University of Indonesia (2009)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Jawa Barat 5 (2022-Sekarang) • <i>Business Manager</i> KFD Jawa Barat 2 • Business Manager of KFD West Java 5 (2022-Present) • Business Manager of KFD West Java 2



Dian Agusdini
Regional Business Manager
Jawa Barat 5
West Java 5 Regional Business Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 32 Tahun 32 years old
Domisili Domicile	: Sleman, Yogyakarta, Indonesia Sleman, Yogyakarta, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Agustus 2009 August 1, 2009
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> Profesi Apoteker, Universitas Gadjah Mada (2012-2013) Sarjana Farmasi, Universitas Gadjah Mada (2008-2012) Pharmacist Profession, Gadjah Mada University (2012-2013) Bachelor of Pharmacy, Gadjah Mada University (2008-2012)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> Business Manager KFD Jakarta 1 (2021-Sekarang) Business Manager KFD Jatimbalinusra (2019-2020) PHM Kimia Farma 159 PT Kimia Farma Apotek (2016-2018) Business Manager of KFD Jakarta 1 (2021-Present) Business Manager of KFD Jatimbalinusra (2019-2020) PHM Kimia Farma 159 of PT Kimia Farma Apotek (2016-2018)



Dandiko Galanova
Regional Business Manager Jakarta 1
Jakarta 1 Regional Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 40 Tahun 40 years old
Domisili Domicile	: Semarang, Jawa Tengah, Indonesia Semarang, Central Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Desember 2008 December 1, 2008
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> Profesi Apoteker, Institut Teknologi Bandung (2008) Sarjana Farmasi, Institut Teknologi Bandung (2005) Profession of Pharmacist, Bandung Institute of Technology(2008) Bachelor of Pharmacy, Bandung Institute of Technology (2005)
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> Business Manager KFD Unit Bisnis Jawa Tengah 1 (2021-Sekarang) PJ Manager Unit Bisnis Klinik Balikpapan (2018) PHM Kimia Farma 288 (2016) Business Manager of KFD Central Java Business Unit 1 (2021-Present) PJ Manager of Balikpapan Clinic Business Unit (2018) PHM Kimia Farma 288 (2016)



Firdaus Sitepu
Regional Business Manager
Jawa Tengah 1
Central Java 1 Regional Business
Manager



Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 40 Tahun 40 years old
Domisili Domicile	: Sidoarjo, Jawa Timur, Indonesia Sidoarjo, East Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Maret 2005 March 1, 2005
Riwayat Pendidikan Educational Background	: Sarjana Management, STIE Al Anwar Mojokerto Bachelor of Management, STIE Al Anwar Mojokerto
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Jawa Timur 1 (2021-Sekarang) • <i>Business Manager</i> KFD Jawa Tengah 2 (2020-2021) • <i>Service Manager</i> Laboratorium Kimia Farma Pontianak (2016-2020) • Business Manager of KFD East Java 1 (2021-Present) • Business Manager of KFD Central Java 2 (2020-2021) • <i>Service Manager</i> of Pontianak Pharmacy Laboratory (2016-2020)



Ary Rahmad Hidayat
Plt. Business Manager Jawa Barat 1
Acting West Java 1 Business Manager

Menjabat Sejak Served Since	: Agustus 2021 August 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 30 Tahun 30 years old
Domisili Domicile	: Manado, Sulawesi Utara, Indonesia Manado, North Sulawesi, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 18 Januari 2016 January 18, 2016
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Apoteker Universitas Airlangga, Surabaya • Sarjana Farmasi Universitas Airlangga, Surabaya • Pharmacist, Airlangga University • Bachelor of Pharmacy, Airlangga University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Regional Bisnis Manager</i> Sulawesi 2 (2021-Sekarang) • PHM Kimia Farma Mapanget • <i>Regional Business Manager</i> Sulawesi 2 (2021-Present) • PHM Kimia Farma Mapanget



Nopriadi Nelintong
Business Manager KFD Sulawesi 2
KFD Sulawesi 2 Business Manager



Menjabat Sejak Served Since	: Agustus 2021 August 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 32 Tahun 32 years old
Domisili Domicile	: Bandar Lampung, Lampung, Indonesia Bandar Lampung, Lampung, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Januari 2015 January 1, 2015
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Profesi Apoteker, Universitas Andalas • Sarjana Farmasi, Universitas Andalas • Pharmacist Profession, Sandals University • Bachelor of Pharmacy, Andalas University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Unit Bisnis Sumatera 4 (2021-Sekarang) • PHM Kimia Farma 628 • Business Manager of KFD Sumatera 4 Business Unit (2021-Sekarang) • PHM Kimia Farma 628



Dolly Martha
Business Manager KFD Sumatera 4
KFD Sumatera 4 Business Manager

Menjabat Sejak Served Since	: Agustus 2021 August 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 44 Tahun 44 years old
Domisili Domicile	: Aceh, Nanggroe Aceh Darussalam, Indonesia Aceh, Nanggroe Aceh Darussalam, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Februari 2006 February 1, 2006
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Profesi Apoteker, Universitas Andalas • Sarjana Farmasi, Universitas Andalas • Pharmacist Profession, Andalas University • Bachelor of Pharmacy, Andalas University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Business Manager</i> KFD Kalimantan 1 (2021-Sekarang) • Kepala Layanan Area Batam (2021) • <i>Business Manager</i> KFA • Business Manager of KFD Kalimantan 1 (2021-Present) • Head of Batam Area Service (2021) • KFA Business Manager



Adhlin Yulsar
Business Manager KFD Kalimantan 1
KFD Kalimantan 1 Business Manager



Menjabat Sejak Served Since	: November 2021 November 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 32 Tahun 32 years old
Domisili Domicile	: Bekasi, Jawa Barat, Indonesia Bekasi, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 April 2015 April 1, 2015
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> Profesi Apoteker, Universitas Airlangga (2013) Sarjana Farmasi, Universitas Airlangga Pharmacist Profession, Universitas Airlangga (2013) Bachelor of Pharmacy, Airlangga University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> Plt. <i>Business Manager</i> KFD Sumatera 2 (2021-Sekarang) Plt. <i>Manager Marketing</i> PT KFD (2021) Asman Sales Acting Business Manager of KFD Sumatera 2 (2021-Sekarang) Acting Manager Marketing of PT KFD (2021) Asman Sales



Andhi Setyawan

Plt. Business Manager KFD Sumatera 2
Acting KFD Sumatera 2 Business Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 50 Tahun 50 years old
Domisili Domicile	: Bekasi, Jawa Barat, Indonesia Bekasi, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Desember 2006 December 1, 2006
Riwayat Pendidikan Educational Background	: Sarjana Ilmu Ekonomi, STIE Adhi Niaga Bachelor of Economics, STIE Adhi Niaga
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> Plt. <i>Business Manager</i> KFD Sumatera 2 (2021-Sekarang) <i>Business Manager</i> Jaya 2 & Bodabek Banten Acting Business Manager of KFD Sumatera 2 (2021-Sekarang) Business Manager of Jaya 2 & Bodabek Banten



Dewi Yustitia

Business Manager KFD Banten 2
KFD Banten 2 Business Manager



Menjabat Sejak Served Since	: Mei 2021 May 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 45 Tahun 45 years old
Domisili Domicile	: Bekasi, Jawa Barat, Indonesia Bekasi, West Java, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 November 2001 November 1, 2001
Riwayat Pendidikan Educational Background	<ul style="list-style-type: none"> • Pendidikan Profesi, Apoteker Universitas Gadjah Mada • Sarjana Farmasi, Universitas Gadjah Mada • Pharmacist Professional Education, Gadjah Mada University • Bachelor of Pharmacy, Gadjah Mada University
Riwayat Pekerjaan Employment History	<ul style="list-style-type: none"> • Plt. <i>Manager Operasional & Service</i> (Mei 2021-Desember 2021) • Ahli Madya PMO (2021) • <i>Business Manager</i> Klinik Bekasi (2020) • Acting Operations & Service Manager (May 2021-December 2021) • Associate PMO (2021) • Bekasi Clinic Business Manager (2020)



Bambang Yuniarto
Plt. Manager Operasional & Service
Acting Operations & Service Manager

Menjabat Sejak Served Since	: Januari 2021 January 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 38 Tahun 38 years old
Domisili Domicile	: Jakarta, DKI Jakarta, Indonesia Jakarta, DKI Jakarta, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Agustus 2008 August 1, 2008
Riwayat Pendidikan Educational Background	<ul style="list-style-type: none"> • Pendidikan Profesi, Apoteker Universitas Airlangga • Sarjana Farmasi, Universitas Airlangga • Pharmacist Professional Education, Airlangga University • Bachelor of Pharmacy, Airlangga University
Riwayat Pekerjaan Employment History	<ul style="list-style-type: none"> • <i>Manager HCBP & GA</i> (2020-2021) • <i>Asman Organization Development</i> (2020) • PHM Kimia Farma Palembang • HCBP & GA Manager (2020-2021) • <i>Asman Organization Development</i> (2020) • PHM Kimia Farma Palembang



Erwan Saefurrohman
Manager HCBP & GA
HCBP & GA Manager



Menjabat Sejak Served Since	: Maret 2021 Maret 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 35 Tahun 35 years old
Domisili Domicile	: Banguntapan, Yogyakarta, Indonesia Banguntapan, Yogyakarta, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 Mei 2012 May 1, 2012
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Pendidikan Profesi Apoteker, Universitas Gadjah Mada • Sarjana Farmasi, Universitas Gadjah Mada • Pharmacist Professional Education, Gadjah Mada University • Bachelor of Pharmacy, Gadjah Mada University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Manager Business Development</i> (2021) • <i>Business Manager</i> KF Gorontalo PT Kimia Farma Apotek • <i>Asman Innovation Team</i> PT Kimia Farma Apotek • <i>Manager Business Development</i> (2021) • <i>Business Manager</i> of KF Gorontalo PT Kimia Farma Apotek • <i>Asman Innovation Team</i> PT Kimia Farma Apotek



Muhammad Arfian Bela Mahardika
Manager Business Developmet
Business Development Manager

Menjabat Sejak Served Since	: November 2021 November 2021
Data Pribadi Personal Data	
Warga negara Citizenship	: Indonesia Indonesian
Usia Age	: 28 Tahun 28 years old
Domisili Domicile	: Jakarta, DKI Jakarta, Indonesia Jakarta, DKI Jakarta, Indonesia
Bergabung di Kimia Farma Joined Kimia Farma	: 1 April 2018 April 1, 2018
Riwayat Pendidikan Educational Background	: <ul style="list-style-type: none"> • Magister Pendidikan Akuntansi, Universitas Udayana • Sarjana Pendidikan Akuntansi, Universitas Udayana • Master of Accounting Education, Udayana University • Bachelor of Accounting Education, Udayana University
Riwayat Pekerjaan Employment History	: <ul style="list-style-type: none"> • <i>Plt. Manager</i> Akuntansi & Keuangan (November-Desember 2021) • <i>Asman Keuangan</i> (November 2021) • <i>Asman Subsidiary Performance Management</i> (Maret 2021-Juli 2021) • <i>Acting Manager</i> of Accounting & Finance (November-December 2021) • <i>Asman Finance</i> (November 2021) • <i>Asman Subsidiary Performance Management</i> (March 2021-July 2021)



I Gusti Putu Oka Surya Utama
Plt. Manager Akuntansi & Keuangan
Acting Manager of Accounting & Finance




DEMOGRAFI KARYAWAN

EMPLOYEE DEMOGRAPHICS

Pegawai PT Kimia Farma Diagnostika

Number of Employees of PT Kimia Farma Diagnostika




● Pegawai Tetap
Permanent Employees
● Pegawai Tidak Tetap
Non-Permanent Employees

Entitas Entity	Laki-laki Male	Perempuan Female	Laki-laki Male	Perempuan Female
PT Kimia Farma Diagnostika	231	671	25,6%	74,4%

KOMPOSISI PEGAWAI BERDASARKAN LEVEL JABATAN

EMPLOYEE COMPOSITION BASED ON POSITION



● Manager
● Asisten Manager
● Supervisor
● Pelaksana
Staff




KOMPOSISI PEGAWAI BERDASARKAN LEVEL JABATAN

EMPLOYEE COMPOSITION BASED ON POSITION

Level Jabatan Position	Persentase Percentage	Jumlah Amount
Manager	0,33%	3
Asisten Manager Assistant Manager	3,67%	33
Supervisor	5,90%	53
Pelaksana Staff	90,1%	810
Total	100%	899

KOMPONEN PEGAWAI BERDASARKAN JURUSAN


EMPLOYEE COMPONENTS BASED ON MAJOR





KOMPONEN PEGAWAI BERDASARKAN GENERASI UMUR

EMPLOYEE COMPONENTS BASED ON AGE GENERATION




Kelompok Generasi Generation Group	Rentang Usia (Tahun) Age Range (Years)	Jumlah Amount
Gen Z	(5-25)	233
Gen Y	(26-40)	616
Gen X	(41-55)	52
Baby Boomer	(56>)	1



STRUKTUR KIMIA FARMA **DIAGNOSTIKA GRUP**

STRUCTURE OF KIMIA FARMA DIAGNOSTIKA GROUP





PENGHARGAAN **DAN SERTIFIKASI**

AWARDS AND CERTIFICATION



25



MARET | MARCH

2021

Gold Champion
Category Clinical Laboratory

Mark Plus. Inc.



DAFTAR ALAMAT KANTOR BISNIS MANAGER

PT KIMIA FARMA DIAGNOSTIKA

LIST OF ADDRESS OF BUSINESS OFFICE MANAGER OF PT KIMIA FARMA DIAGNOSTIKA

No.	Unit Bisnis Manager Business Unit	Alamat Kantor Office Address	No. Telepon Phone No.
1.	SUMATERA 1	Labklin Medan Kartini Jalan R.A. Kartini Nomor 1, Kel. Madras Hulu, Kec. Medan Polonia, Kota Medan, Sumatera Utara	
2.	SUMATERA 2	Lab Klinik Kimia Farma Pekanbaru Tengkerang Tengah, Kec. Marpoyan Damai, Kota Pekanbaru, Riau 28128	08111261749
3.	SUMATERA 3	Kimia Farma Kalidoni Jl. Residen Abdul Rozak No.9, Kalidoni, Kec. Ilir Tim. II, Kota Palembang, Sumatera Selatan 30163	082179549989
4.	SUMATERA 4	LABKLIN KF LAMPUNG Jalan Gajah Mada No. 60/41 Tanjung Agung Raya, Kota Baru, Kec. Tj. Karang Tim., Kota Bandar Lampung, Lampung 35128	081328516040
5.	SUMATERA 5	Kimia Farma Pantai Gading Komplek Ruko Pantai Gading Blok A1 No 20 - 21, Kecamatan Bengkong, Kelurahan Tanjung Buntung, Batam, Kepulauan Riau.	081353052999
6.	BANTEN 1	KLINIK KF SUDIRMAN CILEGON Jl. Jend. Sudirman No.227, Sumurpecung, Kemang, Kota Serang, Banten 42118	081289081025
7.	BANTEN 2	LABKLIN KF GADING SERPONG Graha Emerald M05/08, Jl. Boulevard Raya Gading Serpong No.2, Pakulonan Bar., Kec. Klp. Dua, Kabupaten Tangerang, Banten 15810	081281658822
8.	JAKARTA 1	KLINIK KF.0152 - PASAR MINGGU Jl. Raya Pasar Minggu Km 19 No 3E-F, RT.3/RW.5, Pejaten Bar., Kec. Ps. Minggu, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta 12510	0811393070
9.	JAKARTA 2	KLINIK KF.0298 - BENHIL Jl. Bendungan Hilir No.60, RW.1, Bend. Hilir, Kecamatan Tanah Abang, Kota Jakarta Pusat, Daerah Khusus Ibukota Jakarta 10270	
10.	JABAR 1	KLINIK KF.0014 - CIHAMPÉLAS Jl. Cihampelas No.7, Pasir Kaliki, Kec. Cicendo, Kota Bandung, Jawa Barat 40171	081119326143
11.	JABAR 2	LABKLIN KF CIREBON, Jl. Tuparev No.85F, Sutawinangun, Kedawung, Cirebon, Jawa Barat 45153	081298979611
12.	JABAR 3	Labklin KF Garut Jl. Kabupaten No.01, RT.1/RW.1, Paminggir, Kec. Garut Kota, Kabupaten Garut, Jawa Barat 44151	081223515220
13.	JABAR 4	KLINIK KF.0352 - MARGONDA Jl. Margonda Raya No.326, Kemiri Muka, Kecamatan Beji, Kota Depok, Jawa Barat 16424	081364009697
14.	JABAR 5	KLINIK KF.0508 - NUSANTARA Jl. Bharata Raya No. 1, Sukaharja, Telukjambe Timur, Karawang Barat	081213954563
15.	JATENG 1	LABKLIN KF Semarang Sutomo JL. DR. SUTOMO NO. 3	08114007420
16.	JATENG 2	LABKLIN KF YOGYAKARTA ADISUCIPTO Jl. Laksda Adisucipto No.63A, Ambarukmo, Caturtunggal, Kec. Depok, Kabupaten Sleman, Daerah Istimewa Yogyakarta 55281	08121680432
17.	JATIM 1	Apotek Kimia Farma - Diponegoro (Surabaya) Jl. Residen Abdul Rozak No.9, Kalidoni, Kec. Ilir Tim. II, Kota Palembang, Sumatera Selatan 30163	
18.	JATIM 2	LABKLINIK KF MALANG Jl. Kawi No.22 A, Kauman, Kec. Klojen, Kota Malang, Jawa Timur 65116	08563380510
19.	BALINUSRA	Apotek Kimia Farma Gunung Agung Jl. Gunung Agung No. 88, Pemecutan Kaja, Denpasar Barat - Denpasar	085352180222
20.	KALIMANTAN 1	KLINIK KF.0329 - KILO 5 JL. SOEKARNO HATTA KM 5 NO. 86 E-F	085271333214




No.	Unit Bisnis Manager Manager Business Unit	Alamat Kantor Office Address	No. Telepon Phone No.
21.	KALIMANTAN 2	KLINIK KF.0477 - SUNGAI RAYA DALAM Jl. Sungai Raya Dalam, Sungai Raya, Kec. Pontianak Tenggara, Kota Pontianak, Kalimantan Barat 78116	081364545438
22.	KALIMANTAN 3	KLINIK KF.0733 - PRAMUKA Jl. Pramuka, No. 10, Kec. Pemurus Luar, Banjarmasin Timur, Banjarmasin	081180103065
23.	SULAWESI 1	Labklinik KF A.Yani Jl. Ahmad Yani No.17-19, Pattunuang, Kec. Wajo, Kota Makassar, Sulawesi Selatan 90174	081342514512
24.	SULAWESI 2	Kimia Farma Citraland Jl. Ring Road No.5, Bumi Nyiur, Kec. Wanea, Kota Manado, Sulawesi Utara 95161	085278983326
25.	SULAWESI 2	Kimia Farma Citraland Jl. Ring Road No.5, Bumi Nyiur, Kec. Wanea, Kota Manado, Sulawesi Utara 95161	081257194399
26.	SUMATERA 4	LABKLIN KF LAMPUNG Jalan Gajah Mada No. 60/41 Tanjung Agung Raya, Kota Baru, Kec. Tj. Karang Tim., Kota Bandar Lampung, Lampung 35128	085274656582



INFORMASI PADA **SITUS WEB** **PERUSAHAAN**

INFORMATION ON COMPANY WEBSITE



Situs Web Kimia Farma Diagnostika senantiasa memperbaharui konten dalam situs web untuk memberikan layanan informasi kepada seluruh pemangku kepentingan.

Kimia Farma Diagnostika constantly updates the content on its website to provide information to all stakeholders.

Situs Web Kimia Farma Diagnostika menginformasikan hal-hal sebagai berikut :

Kimia Farma Diagnostika's website informs the following matters:

No.	Konten Situs Web Website Contents	Ketersediaan dalam situs web Kimia Farma Diagnostika Availability in Kimia Farma Diagnostika Website
1.	Nama, alamat dan kantor pusat serta alamat outlet Name, address and head office and outlet address	√
2.	Riwayat Singkat Perseroan Brief History of the Company	√
3.	Profil Direksi dan Dewan Komisaris Board of Directors and Board of Commissioners Profile	√
4.	Informasi Tata Kelola Perusahaan Information on Corporate Governance	√
5.	Penghargaan dan Sertifikasi Awards and Certifications	√
6.	Informasi Produk dan Layanan Kesehatan Information on Product and Health Service	√

√ = tersedia pada situs web Kimia Farma Diagnostika
 X = belum tersedia pada situs web Kimia Farma Diagnostika
 N/A = tidak sesuai dengan kebutuhan Kimia Farma Diagnostika

√ = available on Kimia Farma Diagnostika website
 X = not yet available on Kimia Farma Diagnostika website
 N/A = not in accordance with the needs of Kimia Farma Diagnostika





ANALISA & PEMBAHASAN MANAJEMEN

MANAGEMENT DISCUSSION & ANALYSIS

2021 Laporan Tahunan
Annual report



TINJAUAN KEUANGAN

FINANCIAL OVERVIEW



LAPORAN POSISI KEUANGAN KONSOLIDASIAN

STATEMENTS OF CONSOLIDATED FINANCIAL POSITION

Aset Assets

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Aset Lancar Current Assets	474.548	280.514	194.034	69,17%
Aset Tidak Lancar Non-Current Assets	82.579	64.036	18.443	28,80%
Jumlah Aset Total Assets	557.027	344.550	212.477	61,67%

Jumlah aset Perseroan tahun 2021 tercatat sebesar Rp5,57 Miliar, naik 61,67% dibandingkan tahun sebelumnya Rp3,45 Miliar. Komposisi aset Perseroan tahun 2021 didominasi oleh aset lancar dengan komposisi mencapai 85,19% dari jumlah aset Perseroan.

Total assets of the Company in 2021 was recorded at Rp5.57 billion, an increase of 61.67% compared to the previous year of Rp3.45 billion. The composition of the Company's assets in 2021 is dominated by current assets, reaching 85.19% of total assets.

Aset Lancar Current Assets

Dalam jutaan rupiah
In Million Rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Aset Lancar Current Assets				
Kas dan Setara Kas Cash and Cash Equivalents	46.783	88.776	(41.993)	-47%



Aset Lancar Current Assets

Dalam jutaan rupiah
In Million Rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Piutang Usaha Accounts Receivable	397.362	152.943	244.419	159,81%
Pihak Berelasi Related Parties	277.087	78.072	199.015	255%
Pihak Ketiga Third Party	120.275	74.871	45.404	61%
Persediaan Supply	18.070	30.946	(12.876)	-42%
Beban dibayar di Muka Expenses Paid in Advance	12.332	7.848	4.484	57%
Total Aset Lancar Total Current Assets	474.548	280.514	194.034	69,17%

Pada 31 Desember 2021, jumlah kas dan setara kas Perseroan mencapai Rp46,78 miliar lebih rendah dibandingkan posisi akhir tahun 2020 sebesar Rp88,78 miliar. Penurunan ini utamanya disebabkan oleh pembayaran utang usaha Perseroan.

Jumlah piutang usaha Perseroan tahun 2021 mengalami kenaikan Rp244,42 miliar atau 159,81% dari Rp152,94 miliar di tahun 2020, menjadi Rp397,36 miliar di tahun 2021. Peningkatan piutang usaha tersebut antara lain disebabkan meningkatnya penjualan kredit sebesar 15,53% dari tahun 2020.

Jumlah persediaan Perseroan di akhir tahun 2021 mencapai Rp18,07 miliar lebih rendah dibandingkan posisi akhir tahun 2020 sebesar Rp30,95 miliar. Penurunan ini utamanya disebabkan oleh meningkatnya jumlah pemakaian yang tercermin dari kenaikan omset yang terjadi pada tahun 2021.

Jumlah beban dibayar di muka Perseroan tahun 2021 mengalami kenaikan Rp4,48 miliar atau 57,14% dari Rp7,85 miliar di tahun 2020, menjadi Rp12,33 miliar di tahun 2021. Peningkatan beban dibayar di muka tersebut antara lain disebabkan meningkatnya aktivitas investasi dan sewa gedung.

Jumlah aset lancar Perseroan tahun 2021 mencapai Rp474,55 miliar, naik sebesar 69,17% dibandingkan tahun sebelumnya sebesar Rp280,51 miliar. Peningkatan jumlah aset lancar tersebut utamanya disebabkan naiknya jumlah piutang usaha dan beban dibayar di muka di tahun 2021.

As of December 31, 2021, the Company's total cash and cash equivalents reached Rp46.78 billion, lower than the position at the end of 2020 of Rp88.78 billion. This decrease was mainly due to the payment of the Company's account payables.

The Company's total account receivables in 2021 increased by Rp244.42 billion or 159.81% from Rp152.94 billion in 2020, to Rp397.36 billion in 2021. The increase in account receivables was partly due to an increase in credit sales of 15.53% from 2020.

The Company's total inventory at the end of 2021 reached Rp18.07 billion, lower than the position at the end of 2020 of Rp30.95 billion. This decrease was mainly due to the increase in the number of usage as reflected in the increase in turnover that occurred in 2021.

The Company's total prepaid expenses in 2021 increased by Rp4.48 billion or 57.14% from Rp7.85 billion in 2020 to Rp12.33 billion in 2021. The increase in prepaid expenses was partly due to increased investment activities and building rent.

Total current assets of Company in 2021 reached Rp474.55 billion, an increase of 69.17% compared to the previous year of Rp280.51 billion. The increase in total current assets was mainly due to the increase in account receivables and prepaid expenses in 2021.



Aset Tidak Lancar

Non-Current Assets

Dalam jutaan rupiah
In Million Rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Aset Tidak Lancar Non-Current Assets				
Aset tetap Fixed Assets	71.169	34.901	36.268	104%
Aset Keuangan Tidak Lancar Lainnya Other Non-Current Financial Assets	2.678	16	2.662	16.955%
Aset Hak Guna Right of Use Assets	7.488	-	7.488	
Aset Lain-lain Other Assets	-	28.398	(28.398)	-100%
Aset Pajak Tangguhan Deferred Tax Assets	1.144	722	422	59%
Total Aset Tidak Lancar Total Non-Current Assets	82.479	64.036	18.443	29%

Jumlah aset tetap Perseroan tahun 2021 tercatat sebesar Rp71,17 miliar, meningkat 104% dari tahun sebelumnya Rp34,90 miliar. Peningkatan aset tetap tersebut disebabkan oleh aktivitas investasi pengembangan labklinik dan pembelian alat baru.

Jumlah aset tidak lancar Perseroan pada akhir tahun 2021 mencapai Rp82,48 miliar, meningkat 28,80% dibandingkan tahun sebelumnya Rp64,04 miliar. Peningkatan tersebut antara lain disebabkan meningkatnya jumlah aset tetap, aset keuangan tidak lancar lainnya, aset hak guna dan aset pajak tangguhan pada tahun 2021.

The Company's total fixed assets in 2021 was recorded at Rp71.17 billion, an increase of 104% from the previous year of Rp34.90 billion. The increase in fixed assets was due to investment in laboratory development and purchase of new equipment.

Total non-current assets of Company at the end of 2021 reached Rp82.48 billion, an increase of 28.80% compared to the previous year of Rp64.04 billion. The increase was partly due to the increase in fixed assets, other non-current financial assets, right-of-use assets and deferred tax assets in 2021.

Liabilitas

Liabilities

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Liabilitas Jangka Pendek Short-Term Liabilities	360.260	231.815	128.445	55%
Liabilitas Jangka Panjang Long-Term Liabilities	5.774	3.720	2.054	55%
Total Liabilitas Total Liabilities	366.035	235.535	130.500	55%

Jumlah liabilitas Perseroan tahun 2021 tercatat sebesar Rp366,03 miliar, naik 55,41% dibandingkan tahun sebelumnya sebesar Rp235,53 miliar. Liabilitas Perseroan tahun 2021 masih didominasi oleh liabilitas jangka pendek, yaitu mencapai 98,42% dari jumlah liabilitas Perseroan.

The Company's total liabilities in 2021 was recorded at Rp366.03 billion, an increase of 55.41% compared to the previous year of Rp235.53 billion. The Company's liabilities in 2021 are still dominated by short-term liabilities, which reached 98.42% of total liabilities.

**Liabilitas Jangka Pendek**

Short-term liabilities

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Liabilitas Jangka Pendek Short-Term Liabilities				
Utang Usaha Accounts Payable				
Pihak Berelasi Related Parties	1.806	12.956	(11.149)	-86%
Pihak Ketiga Third Party	68.976	91.276	(22.299)	-24%
Utang Pajak Tax Debt	27.043	4.196	22.846	544%
Beban Masih Harus Dibayar Expenses Still to be Paid	43.034	9.811	33.233	339%
Utang Lain-Lain Other Debt				
Pihak Berelasi Related Parties	199.097	101.166	97.932	97%
Pihak Ketiga Third Party	20.304	12.411	7.893	64%
Total Liabilitas Jangka Pendek Short-Term Liabilities	360.260	231.815	128.445	55%

Jumlah utang pajak Perseroan tahun 2021 meningkat sebesar Rp22,85 miliar atau 544% menjadi Rp27,04 miliar dari tahun sebelumnya Rp4,20 miliar. Peningkatan tersebut karena adanya kenaikan laba tahun berjalan pada tahun 2021.

The Company's total tax payable in 2021 increased by Rp22.85 billion or 544% to Rp27.04 billion from the previous year of Rp4.20 billion. The increase was due to an increase in profit for the year in 2021.

Jumlah utang lain-lain Perseroan tahun 2021 meningkat sebesar Rp105,82 miliar atau 93,17% menjadi Rp219,40 miliar dari tahun sebelumnya Rp113,58 miliar.

The Company's other debts in 2021 increased by Rp105.82 billion or 93.17% to Rp219.40 billion from the previous year of Rp113.58 billion.

Jumlah liabilitas jangka pendek Perseroan tahun 2021 mencapai Rp360,26 miliar, naik 55% dibandingkan tahun sebelumnya Rp231,81 miliar. Peningkatan jumlah liabilitas jangka pendek tersebut utamanya disebabkan naiknya jumlah utang pajak, beban masih harus dibayar dan utang lain-lain pihak berelasi di tahun 2021.

Total short-term liabilities of the Company in 2021 reached Rp360.26 billion, an increase of 55% compared to the previous year of Rp231.81 billion. The increase in total short-term liabilities was mainly due to an increase in tax payable, accrued expenses and other payables to related parties in 2021.

Liabilitas Jangka Panjang

Long-term Liabilities

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Liabilitas Jangka Panjang Long-Term Liabilities				
Kewajiban Imbalan Kerja Employee Benefit Obligations	5.774	3.720	2.054	55%
Total Liabilitas Jangka Panjang Total Long-Term Liabilities	5.774	3.720	2.054	55%



Jumlah liabilitas jangka panjang Perseroan tahun 2021 tercatat sebesar Rp5,77 triliun meningkat Rp2,05 triliun atau 55,23% dari tahun sebelumnya sebesar Rp3,72 triliun. Peningkatan kewajiban imbalan kerja seiring dengan kenaikan jumlah pegawai pada tahun 2021.

Total long-term liabilities of Company in 2021 was recorded at Rp5.77 trillion, an increase of Rp2.05 trillion or 55.23% from the previous year of Rp3.72 trillion. The increase in employee benefit liabilities is in line with the increase in the number of employees in 2021.

Tabel Rincian Ekuitas

Equity Table

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Ekuitas Equity				
Modal Saham Capital Stock	62.500	62.500	-	0
Saldo Laba Retain Earning				
Ditentukan Penggunaannya Defined Use	21.760	25.607	(3.839)	-15%
Belum ditentukan Penggunaannya Use has not been determined	109.398	22.446	86.951	387%
Komponen ekuitas lain Other equity components	(2.674)	(1.539)	(1.136)	74%
Total Ekuitas Total Equity	190.992	109.015	81.977	75%

Tahun 2021, jumlah Ekuitas Perseroan mengalami peningkatan 75,20% menjadi Rp190,99 miliar, dari tahun sebelumnya Rp109,02 miliar. Peningkatan tersebut antara lain disebabkan oleh kenaikan saldo laba yang belum ditentukan penggunaannya sebesar Rp86,95 miliar atau 387,37% dari Rp109,40 miliar menjadi Rp22,45 miliar. Selain itu, saldo laba yang telah ditentukan penggunaannya menurun sebesar Rp3,84 miliar atau 15% dari Rp25,61 miliar menjadi Rp21,77 miliar pada tahun 2021.

In 2021, total Equity of Company has increased by 75.20% to Rp190.99 billion, from the previous year of Rp109.02 billion. The increase was partly due to an increase in unappropriated retained earnings by Rp86.95 billion or 387.37% from Rp109.40 billion to Rp22.45 billion. In addition, the appropriated retained earnings decreased by Rp3.84 billion or 15% from Rp25.61 billion to Rp21.77 billion in 2021.

Labu Rugi dan Penghasilan Komprehensif Lain Konsolidasi

Consolidated Profit and Loss and Other Comprehensive Income

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Penjualan Sale	639.943	476.566	163.377	34%
Beban Pokok Penjualan Cost of goods Sold	(262.885)	(296.956)	34.072	-11%
Laba Kotor Gross Profit	377.058	179.609	197.449	110%
Laba Usaha Operating Profit	139.708	29.241	110.467	378%
Laba Sebelum Pajak Profit before tax	139.708	29.241	110.467	378%
Manfaat (Beban) Pajak Penghasilan Income Tax Benefit (Expense)	(30.310)	(6.794)	(23.516)	346%
Laba Tahun Berjalan Profit for The Year	109.398	22.446	86.951	387%

**Laba Rugi dan Penghasilan Komprehensif Lain Konsolidasi**

Consolidated Profit and Loss and Other Comprehensive Income

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Pendapatan (Beban) Komprehensif lainnya Other Comprehensive Income (Expense)	1.136	1.475	(339)	-23%
Laba Komprehensif Comprehensive Profit	110.533	23.922	86.612	362%

Tahun 2021 Perseroan mencatat penjualan sejumlah Rp639,94 miliar tumbuh 34,28% dari tahun 2020 sebesar Rp476,57 miliar. Pertumbuhan penjualan sebagian besar didominasi oleh penjualan kepada pihak ketiga sebesar 99,74% atau setara dengan Rp638,29 miliar, hal ini disebabkan adanya peningkatan dari penjualan COVID-19 Related yang terjadi pada tahun 2021. Jumlah tersebut meningkat 36,73% dibandingkan tahun sebelumnya sebesar Rp466,83 miliar. Sedangkan penjualan kepada pihak berelasi mengalami penurunan 83% menjadi sebesar Rp1,65 miliar dari Rp9,73 miliar pada tahun 2020. Dari sisi wilayah, dengan penjualan terbanyak, Jawa masih mendominasi kontribusi penjualan dengan 55%, disusul Sumatera 20%, Sulawesi dan Maluku 12%, Kalimantan sebesar 9%, dan Bali Nusra 4%.

Beban Pokok Penjualan Perseroan pada tahun 2021 sebesar Rp262,88 miliar atau 41,08% terhadap penjualan, mengalami penurunan Rp34,07 miliar, hal ini disebabkan *procurement* terpusat yang berhasil menekan Beban Pokok Penjualan sehingga berdampak pada penurunan rasio beban pokok penjualan terhadap penjualan sebesar 21,23% dibanding tahun 2020 sebesar 62,31%. Dengan Beban Pokok Penjualan tersebut, Perseroan membukukan laba kotor sebesar Rp377,05 miliar, meningkat sebesar 109,93% dibandingkan tahun 2020 yang sebesar Rp179,60 miliar.

Seiring dengan meningkatnya penjualan Perseroan tahun 2021, dan efisiensi beban usaha dan *procurement* terpusat, laba usaha Perseroan mengalami peningkatan 377,78% menjadi Rp139,71 miliar dari tahun sebelumnya Rp29,24 miliar.

Laba bersih Perseroan tahun 2021 naik 387,37% atau sebesar Rp109,40 miliar dibandingkan tahun 2020 yang sebesar Rp22,45 miliar.

In 2021 the Company recorded sales amounted to Rp639.94 billion, growing 34.28% from 2020 of Rp476.57 billion. Sales growth was mostly dominated by sales to third parties of 99.74% or Rp638.29 billion, due to an increase in COVID-19 Related sales that occurred in 2021. This number increased by 36.73% compared to the previous year of Rp466.83 billion. Meanwhile, sales to related parties decreased by 83% to Rp1.65 billion from Rp9.73 billion in 2020. In terms of region, with the most sales, Java still dominated the sales contribution with 55%, followed by Sumatera 20%, Sulawesi and Maluku 12%, Kalimantan 9%, and Bali Nusra 4%.

The Company's Cost of Goods Sold in 2021 amounted to Rp262.88 billion or 41.08% of sales, a decrease of Rp34.07 billion, due to centralized procurement that has been succeeded in suppressing Cost of Goods Sold resulting in a decrease in the ratio of cost of goods sold to sales by 21.23% compared to 2020 of 62.31%. With such Cost of Goods Sold, the Company recorded a gross profit of Rp377.05 billion, an increase of 109.93% compared to 2020 amounted to Rp179.60 billion.

Along with the increase in the Company's sales in 2021, and the efficiency of operating expenses and centralized procurement, the Company's operating profit increased by 377.78% to Rp139.71 billion from the previous year of Rp29.24 billion.

The Company's net profit in 2021 increased by 387.37% or Rp109.40 billion compared to Rp22.45 billion in 2020.



Laporan Arus Kas

Statement of Cash Flows

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Arus Kas dari Aktivitas Operasi Cash Flow from Operating activities	104.272	126.290	(22.017)	-17%
Arus Kas dari Aktivitas Investasi Cash Flow from Investment Activities	(34.032)	(20.536)	(13.495)	66%
Arus Kas dari Aktivitas Pendanaan Cash Flow from Funding Activities	(112.233)	(57.408)	(54.825)	96%
Kenaikan (penurunan) Neto Kas dan Setara Increase (decrease) in Net Cash and Cash	(41.992)	48.346	(90.338)	-187%
Kas dan Setara Kas Awal Tahun Cash and Cash Equivalents at Early Year	88.776	40.430	48.346	120%
Kas dan Setara Kas Akhir Tahun Cash and Cash Equivalents at End of Year	46.784	88.776	(41.992)	-47%

Jumlah Kas dan setara kas Perseroan pada akhir periode 2021 mengalami penurunan Rp41,99 miliar atau 47% dibandingkan posisi pada awal tahun 2021. Penurunan tersebut disebabkan oleh adanya optimalisasi *cash management* antar pihak berelasi.

The Company's total cash and cash equivalents at the end of the 2021 period decreased by Rp41.99 billion or 47% compared to the position at the beginning of 2021. The decrease was due to the optimization of cash management between related parties.

Tabel Arus Kas dari Operasi

Cash Flow from Operation

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Arus kas dari aktivitas operasi Cash flow from operating				
Penerimaan kas dari pelanggan Cash receipts from customers	594.539	713.622	(119.083)	-17%
Pembayaran kas kepada pemasok Cash payments to suppliers	(459.854)	(568.219)	108.365	-19%
Pembayaran pajak penghasilan Income tax payment	(30.412)	(19.131)	(11.281)	59%
Penerimaan (Pembayaran) Lainnya Other Operational Receipts	(1)	18	(19)	-104%
Kas Bersih Digunakan untuk Aktivitas Operasi Net Cash Used for Operating	104.272	126.290	22.017	17%



Arus kas dari aktivitas operasi bersih yang diperoleh Perseroan pada tahun 2021 adalah positif sebesar Rp104,27 miliar, turun sebesar Rp22,01 miliar atau 17% dari tahun sebelumnya. Penurunan ini dikarenakan adanya dampak ekonomi atas pandemi COVID-19 yang menyebabkan penurunan tingkat kolektibilitas piutang.

Net cash flow from operating activities obtained by the Company in 2021 was positive at Rp104.27 billion, a decrease of Rp22.01 billion or 17% from the previous year. This decrease was due to the economic impact of the COVID-19 pandemic which caused a decrease in the collectability of receivables.

Tabel Arus Kas Investasi

Cash Flow from Investment

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Arus kas dari aktivitas investasi Cash flow from investment activities				
Perolehan aset tetap Acquisition of fixed assets	(24.761)	(13.946)	(10.815)	78%
Penambahan renovasi aset sewa Addition of renovation of rental assets	(9.271)	(6.590)	(2.681)	41%
Kas bersih diperoleh dari aktivitas investasi Net cash retrieved from investment	(34.032)	(20.536)	(13.496)	66%

Arus kas investasi tahun 2021 adalah sebesar Rp34,03 miliar, naik sebesar Rp13,49 miliar atau 66%. Hal ini seiring dengan program kerja perusahaan yang bertujuan untuk meningkatkan pelayanan kesehatan masyarakat di era pandemi COVID-19 dengan melakukan pengembangan infrastruktur dan peremajaan fasilitas Kesehatan di outlet PT Kimia Farma Diagnostika.

Cash flow from investment in 2021 amounted to Rp34.03 billion, an increase of Rp13.49 billion or 66%. This is in line with the Company's work program aimed to improve public health services in the era of the COVID-19 pandemic by developing infrastructure and rejuvenating health facilities at the outlets of PT Kimia Farma Diagnostika.

Tabel Arus Kas Pendanaan

Cash Flow from Financing

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021	2020	Pertumbuhan (Penurunan) Increase (Decrease)	
			Rp	%
Arus kas dari aktivitas Pendanaan Cash flow from funding activities				
Pembayaran hutang pihak berelasi And related parties	(85.948)	(50.000)	(35.948)	72%
Pembayaran dividen Dividend payment	(26.285)	(7.408)	(18.877)	255%
Kas bersih diperoleh dari aktivitas pendanaan Net cash obtained from funding activities	(112.233)	(57.408)	(54.825)	96%

Sedangkan arus kas yang berasal dari aktivitas pendanaan negatif sebesar Rp112,2 miliar. Meningkatnya pembayaran pada arus kas pendanaan di tahun 2021 dikarenakan adanya optimalisasi *cash management* antar pihak berelasi.

Meanwhile, cash flow from financing activities was negative at Rp112.2 billion. The increase in payments on financing cash flow in 2021 was due to the optimization of cash management between related parties.



Tabel Rasio Keuangan Penting
Key Financial Ratio

Dalam jutaan rupiah
In million rupiah

Rasio Keuangan Penting Financial Ratio Highlights	2021	2020
Rasio Likuiditas Liquidity Ratio		
Current Ratio	132%	121%
Acid Test Ratio	127%	108%
Cash Ratio	13%	38%
Rasio Solvabilitas Solvability Ratio		
Solvability	152%	146%
Debt Ratio	66%	68%
Equity Ratio	34%	32%
Debt to Equity Ratio	192%	216%
Rasio Rentabilitas Rentability Ratio		
ROI	321%	109%
ROE	57%	21%
ROA	20%	7%
EBITDA Margin	12%	3%
Rasio Operasional Operational Ratio		
Hari Perputaran Piutang Receivable Turnover Day	379	123
Hari Perputaran Persediaan Inventory Turnover Day	33	180
Hari Perputaran Utang Dagang Accounts Payable Turnover Day	19	52
Cash to Cash Cycle	293	251

KEMAMPUAN MEMBAYAR UTANG DAN TINGKAT KOLEKTIBILITAS PIUTANG

Kemampuan Perseroan dalam memenuhi seluruh kewajiban baik kewajiban jangka pendek maupun jangka panjang, diukur melalui beberapa rasio, antara lain rasio likuiditas dan rasio solvabilitas. Tingkat kolektibilitas piutang dicerminkan melalui umur piutang.

ABILITY TO PAY DEBT AND RECEIVABLES COLLECTIBILITY RATE

The Company's ability to meet its entire obligations, both short-term and long-term, is measured through several ratios, including liquidity ratio and solvency ratio. The receivables collectability rate is reflected in the age of receivables.

Tabel Rasio Likuiditas
Liquidity Ratio

Dalam jutaan rupiah
In million rupiah

Rasio Keuangan Penting Financial Ratio Highlights	2021	2020
Rasio Likuiditas Liquidity Ratio		
Cash Ratio	13%	38%
Current Ratio	132%	121%

KEMAMPUAN MEMBAYAR UTANG JANGKA PENDEK

Kemampuan Perseroan dalam memenuhi kewajiban jangka pendek diukur dari rasio likuiditas. Pada akhir tahun 2021, jumlah kas dan setara kas Perseroan sebesar Rp46,7 miliar, jumlah aset lancar sebesar Rp474,5 miliar dan jumlah liabilitas jangka pendek Perseroan adalah sebesar Rp360,3 miliar.

ABILITY TO PAY SHORT-TERM DEBTS

The Company's ability to meet short-term debts is measured by liquidity ratio. At the end of 2021, the Company's total cash and cash equivalents amounted to Rp46.7 billion, total current assets amounted to Rp474.5 billion and total short-term liabilities amounted to Rp360.3 billion.



Tabel Solvabilitas
Solvency

Dalam jutaan rupiah
In million rupiah

Rasio Keuangan Penting Financial Ratio Highlights	2021	2020
Rasio Solvabilitas Solvency Ratio		
Debt Ratio	66%	68%
Debt to Equity Ratio	192%	216%

KEMAMPUAN MEMBAYAR TOTAL UTANG

Kemampuan Perseroan dalam membayar utang jangka panjang dapat dilihat dari rasio solvabilitas yang terdiri dari *debt ratio* dan *debt to equity ratio*. Tahun 2021, *debt ratio* Perseroan adalah sebesar 66%, turun dari tahun sebelumnya 68%, sedangkan *debt to equity ratio* Perseroan adalah sebesar 192%, yang juga turun dari tahun sebelumnya 216%.

ABILITY TO PAY TOTAL DEBT

The Company's ability to pay long-term debts can be seen from solvency ratio, which consists of debt ratio and debt to equity ratio. In 2021, the Company's debt ratio is 66%, down from the previous year's 68%, while the Company's debt to equity ratio is 192%, which is also down from the previous year's 216%.

Tabel Tingkat Kolektibilitas Piutang Berdasarkan Umur
Receivables Collectability Rate by Age

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021		2020		Pertumbuhan (Penurunan) Increase (Decrease)	
	Jumlah Rp Juta Total Million Rp	Komposisi % Composition %	Jumlah Rp Juta Total Million Rp	Komposisi % Composition %	Rp	%
1-30 Hari 1-30 Days	130.263	33%	79.932	52%	50.331	21%
31-60 Hari 31-60 Days	20.639	5%	18.995	12%	1.644	1%
61-90 Hari 61-90 Days	221.185	6%	14.280	9%	206.905	85%
Lebih dari 90 hari More than 90 days	25.383	100%	39.978	26%	(14.596)	-6%
Jumlah Amount	397.470		153.186	100%	244.285	100%
Cadangan kerugian penurunan nilai Allowance for Impairment Losses	(108)		(242)		134	
Jumlah Piutang Usaha-Bersih Total Accounts	397.362		152.943		244.419	160%

TINGKAT KOLEKTIBILITAS PIUTANG

Kolektibilitas piutang mencerminkan kemampuan Perseroan dalam menagih piutangnya. Tahun 2021, jumlah piutang usaha Perseroan mencapai Rp397 miliar, naik jika dibandingkan tahun sebelumnya sebesar Rp152,9 miliar.

RECEIVABLES COLLECTABILITY RATE

The receivables collectability reflects the Company's ability to collect its receivables. In 2021, the Company's total account receivables reached Rp397 billion, an increase compared to the previous year of Rp152.9 billion.



STRUKTUR MODAL

CAPITAL STRUCTURE

KEBIJAKAN STRUKTUR MODAL

Tahun 2021, struktur modal Perseroan masih didominasi oleh Liabilitas dengan komposisi sebesar 66%. Komposisi tersebut sedikit mengalami perubahan, namun dengan kecenderungan penguatan yang ekuitas yang cukup baik.

CAPITAL STRUCTURE POLICY

In 2021, the Company's capital structure is still dominated by liabilities with a composition of 66%. The composition has slightly changed, but with a fairly good tendency to strengthen equity.

Tabel Tingkat Kolektibilitas Piutang Berdasarkan Umur

Receivables Collectability Rate by Age

Dalam jutaan rupiah
In million rupiah

Uraian Description	2021		2020	
	Jumlah Rp Juta Total Million Rp	Komposisi % Composition %	Jumlah Rp Juta Total Million Rp	Komposisi % Composition %
Liabilitas Jangka Pendek Short-Term Liabilities	360.260	65%	231.815	67%
Liabilitas Jangka Panjang Long-Term Liabilities	5.774	1%	3.720	1%
Jumlah Liabilitas Total Liabilities	366.035	66%	235.535	68%
Jumlah Ekuitas Total Equity	190.992	34%	109.015	32%
Jumlah Liabilitas dan Ekuitas Total Liabilities and Equity	557.027	100%	344.550	100%

LAYANAN KFD

KFD SERVICE

PENDAPATAN BERDASARKAN SEGMENT WILAYAH

REVENUE BY GEOGRAPHICAL SEGMENT

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017
Jawa	350.479	397.482	111.794	81.046	56.975
Sumatera	128.369	76.070	31.684	20.029	20.881
Sulawesi dan Maluku	76.756	43.072	23.576	17.786	-
Kalimantan	56.599	33.612	10.780	9.172	-
Bali dan Nusa Tenggara	27.740	26.330	4.208	1.911	25.362
Jumlah Total	639.943	476.566	182.942	129.942	103.218

IKHTISAR KEUANGAN

FINANCIAL OVERVIEW

LAPORAN POSISI KEUANGAN KONSOLIDASIAN

STATEMENTS OF CONSOLIDATED FINANCIAL POSITION

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020- 2021%	CAGR 2017-2021%
Aset Lancar Current Assets	474.548	280.514	109.239	72.925	30.373	169%	99%
Aset Tidak Lancar Non-Current Assets	82.479	64.036	49.096	31.076	9.468	129%	72%
Jumlah Aset Total Assets	557.027	344.550	158.335	104.631	39.841	162%	93%
Liabilitas Jangka Pendek Short-Term Liabilities	360.260	231.815	64.163	15.438	8.095	155%	158%



Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020- 2021%	CAGR 2017-2021%
Liabilitas Jangka Panjang Long-Term Liabilities	5.774	3.720	1.061	777	442	155%	90%
Jumlah Liabilitas Total Liabilities	366.035	235.535	65.224	16.215	8.537	155	156%
Jumlah Ekuitas Total Equity	190.992	109.015	93.111	88.417	31.304	175%	57%

**LAPORAN LABA RUGI DAN PENGHASILAN
KOMPREHENSIF LAINNYA KONSOLIDASIAN**
**CONSOLIDATED STATEMENTS OF PROFIT
(LOSS) AND OTHER COMPREHENSIVE INCOME**

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020- 2021%	CAGR 2017-2021%
Penjualan Sale	639.943	476.566	182.042	129.942	103.218	134%	58%
Beban Pokok Penjualan Cost of goods Sold	(262.885)	(296.956)	(80.493)	(52.085)	(44.858)	89%	56%
Laba Kotor Gross Profit	377.058	179.609	101.549	77.857	58.360	210%	59%
Biaya Usaha Operating Income	(237.351)	(150.369)	(91.207)	(67.758)	(49.974)	158%	48%
Laba Usaha Operating Profit	139.708	29.241	10.342	10.100	8.386	478%	102%
Beban Keuangan	-	-	-	41	183	0%	0%
Laba Sebelum Pajak Profit before tax	139.708	29.241	10.342	10.342	8.260	478%	103%
Penghasilan Income Tax Benefits (Expenses)	(30.310)	(6.749)	(2.829)	(2.829)	(2.260)	446%	91%
Laba Tahun Berjalan Profit for The Year	109.398	22.446	7.514	7.514	6.000	487%	107%
Komprehensif lainnya (expenses)	1.136	1.475	81	81	(357)	77%	0%
Laba Komprehensif Comprehensive Profit	110.533	23.922	7.594	7.594	5.643	462%	110%

LAPORAN ARUS KAS KONSOLIDASIAN
**STATEMENTS OF CONSOLIDATED CASH
FLOWS**

Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020- 2021%	CAGR 2017-2021%
Arus Kas dari Aktivitas Operasi Cash Flow from Operating activities	104.272	126.290	(13.499)	(4.387)	1.895	83%	172%
Arus Kas dari Aktivitas Investasi Cash Flow from Investment Activities	(34.032)	(20.536)	(20.798)	(26.380)	(26.353)	166%	95%
Arus Kas dari Aktivitas Pendanaan Cash Flow from Funding Activities	(112.233)	(57.408)	50.290	48.000	2.131	196%	0%
Kas dan Setara Kas Cash and Cash Equivalents	(41.992)	48.346	15.993	17.234	1.673	-87%	0%
Terhadap kas dan setara kas Effects on Cash and Cash Equivalent	-	-	-	-	-	0%	0%
Kas dan Setara Kas Awal Tahun Cash and Cash Equivalents at Early Year	88.776	40.430		7.204	5.531	220%	100%



Dalam jutaan rupiah In million rupiah	2021	2020	2019	2018	2017	YoY 2020- 2021%	CAGR 2017-2021%
Kas dan Setara Kas Akhir Tahun Cash and Cash Equivalents at End of Year	46.784	88.776		24.438	7.204	53%	60%
Investasi Investment	-	-	-	-	-	0%	0%

RASIO - RASIO KEUANGAN

FINANCIAL RATIO

Keterangan Description	2021 Audit	2020 Audit	2019 Audit	2018 Audit	2017 Audit
Imbal Hasil Investasi Return on Investment	321%	109%	36%	27%	255%
Imbal Hasil Ekuitas Return on Equity	57%	21%	8%	8%	19%
Imbal Hasil Aset Return on Assets	25%	8%	5%	7%	15%
Margin Laba Kotor Gross Profit Margin	59%	38%	56%	60%	57%
Margin Laba Bersih Net Profit Margin	17%	4,7%	4,1%	5,6%	5,8%
Rasio Perputaran Aset Asset Turnover Ratio	142,0%	189,5%	138,5%	179,9%	279,6%
Rasio Lancar Current Ratio	132%	121%	170%	472%	375%
89% Rasio Cepat Quick Ratio	13%	38%	63%	158%	89%
Rasio Utang Jangka Panjang Long Term Debt Ratio	3,0%	3,4%	1,1%	0,9%	1,4%
Rasio Liabilitas Terhadap Jumlah Aset Liability to Total Assets Ratio	68%	41%	41%	15%	21%
Rasio Liabilitas Terhadap Ekuitas Liability to Equity Ratio	192%	216%	27%	18%	70%







FUNGSI PENUNJANG **BISNIS**

BUSINESS SUPPORTING FUNCTION

2021 Laporan Tahunan
Annual report



SUMBER DAYA MANUSIA

HUMAN CAPITAL



Keberlanjutan dan keunggulan kompetitif Perseroan sangat tergantung pada Sumber Daya Manusia (SDM) yang mampu beradaptasi dengan segala perubahan. Strategi pengelolaan SDM diperlukan dalam menyiapkan sumber daya manusia yang produktif dan memiliki loyalitas kepada Perseroan sekaligus mampu menghasilkan SDM unggul yang berbakat (*Talent*) serta memiliki daya saing.

Pada tahun 2021, adanya pandemi COVID-19 merupakan tantangan sekaligus peluang bagi Perseroan. Oleh karena itu, Perseroan melakukan optimalisasi bisnis dan penguatan kompetensi teknis khususnya kepada para tenaga kesehatan (ATLM, Perawat & Bidan) untuk mendapatkan peluang serta mendukung program pemerintah dalam mendeteksi dan mencegah penularan virus COVID-19. Di tahun 2021, Perseroan berhasil memperoleh produktivitas pegawai sebesar 249,91 juta/tahun/pegawai atau tumbuh sebesar 144% dibandingkan dengan produktivitas tahun 2020.

Dalam meningkatkan *talent readiness*, Perseroan melakukan program pengembangan pegawai secara konsisten dan berkelanjutan. Di tahun 2021, Perseroan memiliki *talent pool* level BoD-1 sampai BoD-3 sebanyak 35% dari total jumlah pegawai, *Millennial Talent* sebanyak 44% dari total populasi pegawai *millennial* dan *Woman Talent* sebanyak 8,3% dari total populasi Perempuan Perseroan. Angka *talent readiness* Perseroan diharapkan terus meningkat sehingga mampu mempersiapkan *pipeline leadership* di setiap *stream* kompetensi sesuai dengan kebutuhan Perseroan saat ini dan di masa yang akan datang.

The Company's sustainability and competitive advantage is highly dependent on Human Capital (HC) who are able to adapt to all kinds of changes. Human capital management (talent management) strategy is needed in preparing productive human capital with loyalty to the Company as well as to creating superior talented and high-competitive human capital (talent).

In 2021, the COVID-19 pandemic was both a challenge and an opportunity for the Company. Therefore, the Company optimized its business and strengthened technical competencies, especially for health workers (ATLM, Nurses & Midwives) to seize the opportunities and support government programs in detecting and preventing the transmission of the COVID-19 virus. In 2021, the Company succeeded in gaining employee productivity of 249.91 million/year/employee or grew by 144% compared to productivity in 2020.

In increasing talent readiness, the Company organizes employee development programs in a consistent and continuous manner. In 2021, the Company has BoD-1 to BoD-3 level talent pool as much as 35% of total number of employees, Millennial Talent as much as 44% of total millennial employee population and Female Talent as much as 8.3% of total female population of the Company. The Company's talent readiness number is expected to continue to increase so as to be able to prepare a leadership pipeline in each competency stream in accordance with the current and future needs of the Company.



Secara garis besar, beberapa fokus program pengelolaan SDM Perseroan pada tahun 2021 dilakukan melalui:

1. Perbaikan Tata Kelola Organisasi melalui peningkatan pengawasan dan kualitas mutu layanan guna menjamin layanan yang bermutu bagi seluruh pelanggan.
2. Optimalisasi penggunaan sistem kepegawaian untuk meningkatkan kemudahan administrasi pegawai.
3. Penyiapan Sumber Daya Manusia (SDM) yang kompeten sesuai kebutuhan Perseroan.
4. Pelaksanaan *Project Vaksin Gotong Royong* melalui penyiapan tenaga medis yang berkualitas.

Survei Kepuasan pegawai Perseroan yang dilaksanakan di penghujung tahun 2021 diperoleh nilai indeks kepuasan pegawai 3.16 dengan kategori "Baik" dan *Employee Net Promotor Score* (eNPS) yaitu tingkat kemungkinan seorang karyawan mau merekomendasikan perusahaan tempat bekerja kepada teman atau kerabat diperoleh nilai 41.87 dengan kategori "Recommend".

Pencapaian *Man Day Training* di 2021 yaitu sebesar 3,6 hari/tahun/pegawai dengan program pelatihan dan pengembangan yang terstruktur dalam mengembangkan *hard skill* maupun *soft skill* pegawai sebagai berikut :

Broadly speaking, several focuses of the Company's talent management program in 2021 were:

1. Improvement of Organizational Governance through increased supervision and quality of service to ensure quality services for all customers.
2. Optimizing the use of staffing system to improve the ease of employee administration
3. Preparation of competent Human Capital (HC) according to the needs of the Company.
4. Implementation of Mutual Cooperation Vaccine Project through the preparation of qualified medical personnel.

The Company's Employee Satisfaction Survey conducted at the end of 2021 obtained an employee satisfaction index score of 3.16 with "Good" category and the Employee Net Promoter Score (eNPS), namely the probability that an employee would recommend a company where he/she works to friends or relatives, obtained a score of 41.87 with "Recommend" category.

The achievement of Man Day Training in 2021 is 3.6 days/year/employee with structured training and development programs in developing the hard skills and soft skills of employees as follows:

Waktu Penyelenggaraan Organizing Time	Program Material	Peserta Participants
Januari January	Kemampuan Kunci Kepemimpinan BM Leadership Key Capability for BM	Seluruh <i>Regional Business Manager</i> KFD All Regional Business Manager KFD
Februari February	Pengetahuan Produk Sales - IL 6 Product Knowledge Sales - IL 6	Seluruh <i>Marketing</i> KFD All Marketing KFD
	Lokakarya & Sosialisasi Redata Redata Workshop & Socialization	Seluruh <i>Performance Business Support</i> KFD All Performance Business Support KFD
Maret March	Sosialisasi SOP KFD SOP Socialization KFD	Seluruh <i>Service Manager</i> KFD All Service Manager KFD
	<i>Training of Trainer</i> Vaksinator KFD Training of Trainer Vaccinator KFD	PIC Vaksinator KFD PIC Vaccinator KFD
	Sosialisasi SOP KFD SOP Socialization KFD	Seluruh Koordinator KFD All Coordinator KFD
	<i>Succesful Project Management</i>	<i>Quality Management Team</i> KFD Quality Management Team KFD
	Pelatihan Wow Service Wow Service Training	Seluruh RBM & SM KFD All Regional Business Manager & Service Manager KFD
	Sosialisasi SOP KFD SOP Socialization KFD	Seluruh Pj. Mutu KFD All PIC Lab Quality KFD
April April	Lokakarya <i>Performance Business Support</i> Workshop for Performance Business Support	Seluruh PBS KFD All Performance Business Support KFD
	<i>Coaching Program dan Final Presentation</i> - Kimia Farma Diagnostika <i>Development Program - Service Manager</i> KFD	Seluruh SM KFD All Service Manager KFD
	<i>Coaching Program dan Final Presentation</i> - Kimia Farma Diagnostika <i>Development Program - Business Manager</i> KFD	Seluruh RBM KFD All Regional Business Manager KFD
Mei May	<i>Training VTP ISO ADS & ISO 15189</i>	Tim <i>Quality Management</i> KFD Quality Management Team KFD
	Aktivasi AKHLAK AKHLAK Activation	Seluruh Pegawai KFD All KFD Employees
Juni June	<i>Training Plebotomi In-house - Pra-analitik</i> Inhouse Phlebotomy Training - Pre-analytics	Seluruh Perawat KFD All Nurse KFD



Waktu Penyelenggaraan Organizing Time	Program Material	Peserta Participants
	<i>Training Surveillance Sistem Manajemen Anti Penyuapan (SMAP) ISO 37001</i> Anti Bribery Surveillance System ISO 37001 Training	Seluruh Pegawai KFD All KFD Employees
	ToT Vaksinator Tenaga Kesehatan VGR VGR Vaccinator Health Worker Training of Trainers	Tim Vaksinator VGR KFD VGR Vaccinator Team KFD
	ToT Vaksinator Tenaga Kesehatan VGR UB Kalimantan 3 VGR Vaccinator Health Worker Training of Trainers - BU Kalimantan 3	Tim Vaksinator UB Kalimantan 3 KFD VGR Vaccinator Team BU Kalimantan 3 KFD
Juli July	Pelatihan <i>Digital Order & Persiapan KF Premier</i> Training Digital Order & KF Premiere Preparation	Seluruh Pegawai KF Premier All KF Premiere Employees
	Pelatihan <i>Service Experience</i> Service Experience Training	Seluruh Pegawai <i>Outlet</i> KFD All KFD Outlet Employees
Agustus August	Pelatihan Pengenalan <i>One Billing System</i> One Billing System Introductory Training	Seluruh Pegawai <i>Outlet</i> KFD All KFD Outlet Employees
	Pelatihan Proses Bisnis & SOP Klinik & Labklin Klinik & Labklin SOP & Business Process Training	Seluruh Pegawai <i>Outlet</i> KFD All KFD Outlet Employees
	Simulasi & Pelatihan Implementasi Sistem System Implementation Training & Simulation	Seluruh Pegawai <i>Outlet</i> KFD All KFD Outlet Employees
	AKHLAK <i>Warrior</i> KFD	Seluruh Pegawai KFD All KFD Employees
September September	Bincang "Memenangkan Hati dan Loyalitas Pelanggan Anda" "Winning Your Customer's Heart and Loyalty" Talks	Seluruh Pegawai KF Premier All KF Premier Employees
	Sosialisasi Pengetahuan Produk (HBV DNA, M2BPGi, <i>New Born Screening</i>) Product Knowledge Socialization (HBV DNA, M2BPGi, <i>New Born Screening</i>)	Pegawai UB Jabar 1 KFD KFD UB Jabar 1 Employees
Oktober October	<i>Speak to Change for Confident</i>	Seluruh Pegawai KFD All KFD Employees
November November	Pelatihan Manajemen <i>Procurement</i> Lanjutan Advanced Procurement Management Training	Pegawai Unit Operasional KFD KFD Operational Unit Employees
	Pelatihan Tata Kelola Manajemen Pemberitaan News Management Governance Training	KFD <i>Operational Unit</i> Employees KFD Operational Unit Employees
	Pelatihan Manajemen Mutu ATLM Laboratory Analyst & Technician Quality Management Training	ATLM UB Banten 2 KFD Laboratory Analyst & Technician UB Banten 2 KFD
	Lokakarya Unit Pendukung Bisnis Business Unit Support Workshop	Seluruh PBS & Akuntansi Keuangan KFD All PBS & Finance Accounting Employees
Desember December	Lokakarya Sistem Informasi Laboratorium Laboratory Information System Workshop	Tim Manajemen Mutu KFD Quality Management Team KFD
	Lokakarya Akreditasi Laboratorium Laboratory Accreditation Workshop	Tim Manajemen Mutu KFD Quality Management Team KFD
	Lokakarya Penggunaan Alkes & Reagensia di Laboratorium Medical Devices & Reagent Usage in Laboratory Workshop	Tim Manajemen Mutu KFD Quality Management Team KFD
	Lokakarya Pemantapan Mutu Quality Assurance Workshop	Tim Manajemen Mutu KFD Quality Management Team KFD
	Lokakarya Pengelolaan Limbah Medis Waste Management Workshop	Tim Manajemen Mutu KFD Quality Management Team KFD
	Edukasi & Sosialisasi Perpajakan & PPH 21 Taxation & PPH 21 Education & Socialization	All PBS & Finance Accounting Employees All PBS & Finance Accounting Employees







TATA KELOLA PERUSAHAAN

CORPORATE GOVERNANCE

2021 Laporan Tahunan
Annual report



PERKARA PENTING

LEGAL CASE



PERMASALAHAN HUKUM YANG SEDANG DIHADAPI DEWAN KOMISARIS DAN DIREKSI YANG SEDANG MENJABAT

Sepanjang tahun 2021, tidak terdapat kasus hukum yang melibatkan anggota Dewan Komisaris dan Direksi Perseroan.

PERMASALAHAN HUKUM/LITIGASI

Sepanjang 2021, Perseroan tidak memiliki permasalahan hukum baik perdata maupun pidana serta senantiasa memperhatikan aspek kepatuhan terhadap peraturan perundang-undangan yang berlaku dalam menjalankan kegiatan usahanya.

SANKSI ADMINISTRASI YANG DITERIMA PERSEROAN

Sepanjang tahun 2021, Kimia Farma Apotek tidak mendapatkan sanksi administrasi dalam bentuk apapun dari regulator.

LEGAL PROBLEMS FACING THE BOARD OF COMMISSIONERS AND BOARD OF DIRECTORS IN SERVICE

Throughout 2021, there were no legal cases involving members of the Company's Board of Commissioners and Directors

LEGAL/LITIGATION ISSUES

Throughout 2021, the Company did not have any legal issues, either civil or criminal cases, and it has always paid attention to the aspect of compliance with the applicable laws and regulations in conducting its business activities.

ADMINISTRATIVE SANCTIONS RECEIVED BY THE COMPANY

Throughout 2021, Kimia Farma Apotek did not receive any administrative sanctions in any form from the regulator.

HALAMAN SENGAJA DIKOSONGKAN
This page is intentionally left blank

National Market Acquisition
Through **Outstanding Performance**




PT Kimia Farma Diagnostika

Jl. Budi Utomo No.1, Jakarta Pusat

Phone : (+62 21) 3857245 / +62 821-2399-9942

Email : marketingpusat@labkimiafarma.co.id



SCAN ME